

Review

Genes and Athletic Performance: The 2023 Update

Ekaterina A. Semenova ^{1,2} , Elliott C. R. Hall ³ and Ildus I. Ahmetov ^{4,5,6,7,*} 

- ¹ Department of Molecular Biology and Genetics, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, 119435 Moscow, Russia
- ² Research Institute of Physical Culture and Sport, Volga Region State University of Physical Culture, Sport and Tourism, 420138 Kazan, Russia
- ³ Faculty of Health Sciences and Sport, University of Stirling, Stirling FK9 4UA, UK
- ⁴ Laboratory of Genetics of Aging and Longevity, Kazan State Medical University, 420012 Kazan, Russia
- ⁵ Sports Genetics Laboratory, St Petersburg Research Institute of Physical Culture, 191040 St. Petersburg, Russia
- ⁶ Department of Physical Education, Plekhanov Russian University of Economics, 115093 Moscow, Russia
- ⁷ Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool L3 5AF, UK
- * Correspondence: genoterra@mail.ru

Abstract: Phenotypes of athletic performance and exercise capacity are complex traits influenced by both genetic and environmental factors. This update on the panel of genetic markers (DNA polymorphisms) associated with athlete status summarises recent advances in sports genomics research, including findings from candidate gene and genome-wide association (GWAS) studies, meta-analyses, and findings involving larger-scale initiatives such as the UK Biobank. As of the end of May 2023, a total of 251 DNA polymorphisms have been associated with athlete status, of which 128 genetic markers were positively associated with athlete status in at least two studies (41 endurance-related, 45 power-related, and 42 strength-related). The most promising genetic markers include the *AMPD1* rs17602729 C, *CDKN1A* rs236448 A, *HFE* rs1799945 G, *MYBPC3* rs1052373 G, *NFIA-AS2* rs1572312 C, *PPARA* rs4253778 G, and *PPARGC1A* rs8192678 G alleles for endurance; *ACTN3* rs1815739 C, *AMPD1* rs17602729 C, *CDKN1A* rs236448 C, *CPNE5* rs3213537 G, *GALNTL6* rs558129 T, *IGF2* rs680 G, *IGSF3* rs699785 A, *NOS3* rs2070744 T, and *TRHR* rs7832552 T alleles for power; and *ACTN3* rs1815739 C, *AR* ≥ 21 CAG repeats, *LRPPRC* rs10186876 A, *MMS22L* rs9320823 T, *PHACTR1* rs6905419 C, and *PPARG* rs1801282 G alleles for strength. It should be appreciated, however, that elite performance still cannot be predicted well using only genetic testing.



Citation: Semenova, E.A.; Hall, E.C.R.; Ahmetov, I.I. Genes and Athletic Performance: The 2023 Update. *Genes* **2023**, *14*, 1235. <https://doi.org/10.3390/genes14061235>

Academic Editor: Paolo Cinelli

Received: 19 May 2023

Revised: 5 June 2023

Accepted: 7 June 2023

Published: 8 June 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Keywords: sports; genetics; genotype; polymorphism; genomics; physical performance; athletes; GWAS; WGS; WES

1. Introduction

Athletic success is influenced by many genetically determined factors, including transcriptomic, biochemical, histological, anthropometric, physiological, and psychological traits, as well as general health status [1–8]. On average, 66% of the variance in athlete status can be explained by genetic factors [9]. The remaining variance is due to environmental factors, such as deliberate practice, nutrition, ergogenic aids, birthplace, the availability of medical and social support, and even luck (e.g., birthdate) [6,10–12].

Starting in the late 1990s, research began to identify DNA polymorphisms associated with predisposition to certain types of sports and exercise-related phenotypes, with initial focus on variants of the *ACE*, *ACTN3*, *AMPD1*, *PPARA*, *PPARD*, and *PPARGC1A* genes [13–23]. Initially, most research was conducted using the candidate gene approach [24–29], which limited progress in the discovery of new genetic markers associated with exercise- and sport-related phenotypes [30]. In addition to the fact that this approach studies only a single genetic variant in isolation, most candidate gene studies in the field of sports genomics are limited by sample size. This is a potential source of type I error (false positive findings), underpinning why replication of positive associations in independent cohorts is essential.

Conversely, the genome-wide association approach is considered the most efficient study design thus far in identifying genetic markers associated with sport-related characteristics. Indeed, the application of this approach has enabled the discovery of hundreds of single nucleotide polymorphisms (SNPs) directly or indirectly associated with exercise and sport, such as height (12,111 SNPs) [31], appendicular lean mass (1059 SNPs) [32], testosterone levels (855 SNPs) [33], handgrip strength (170 SNPs) [34–36], sarcopenia (78 SNPs) [37], and brisk walking (70 SNPs) [38].

It is important to consider that the discovery of 12,111 independent genome-wide ($p < 5 \times 10^{-8}$) significant SNPs associated with height (which in combination account for 40% of phenotypic variance) required the study of 5.4 million individuals [31]. Accordingly, such findings indicate that each DNA locus is likely to explain only a very small proportion of the reported phenotypic variance (~0.0033%). This also suggests that very large samples of athletes and non-athletic controls are needed to detect a substantial number of genetic markers associated with athlete status, with some suggesting those markers be used as part of talent identification strategies. To date, five genome-wide association (GWAS) studies [39–43], one whole-genome sequencing (WGS) study [44], and one exome-wide association (EWAS) study [45] involving athletic cohorts have been conducted. However, due to their limited sample sizes, these investigations and subsequent replication studies have resulted in the identification of only 13 genetic markers. Six markers were associated with endurance athlete status (*CDKN1A* rs236448 A, *GALNTL6* rs558129 C, *NFIA-AS2* rs1572312 C, *MYBPC3* rs1052373 G, *SIRT1* rs41299232 G, and *TRPM2* rs1785440 G alleles) [39,40,42,43,45,46], five with sprinter/strength athlete status (*AGRN* rs4074992 C, *CDKN1A* rs236448 C, *CPNE5* rs3213537 G, *NUP210* rs2280084 A, and *GALNTL6* rs558129 T alleles) [41,45,47,48], and two with reaction time in wrestlers and athlete status in combat/team sports (*APC* rs518013 A and *LRRN3* rs80054135 T alleles, respectively) [44].

To overcome the issue of small samples of elite athletes, the use of genome-wide significant ($p < 5 \times 10^{-8}$) markers of exercise-related phenotypes (correlated with sport-related traits) discovered in large cohorts of untrained subjects (for example, UK Biobank, FinnGen, BioBank Japan, etc.) was proposed [49,50]. This approach may significantly decrease the risk of obtaining false-positive results in the discovery of markers associated with athlete status, which is recognized as a key limitation of sports genomics studies conducted on limited sample sizes. Accordingly, the first stage of such an investigation is to list candidate genetic markers previously identified in GWAS of exercise-related phenotypes in non-athletic populations. For example, this may include SNPs associated with phenotypes of handgrip strength, brisk walking, physical activity, lean mass, forced vital capacity, haemoglobin, or levels of hormones such as testosterone and IGF1. At the second stage, microarray analysis (with imputation; covering > 10 million SNPs) is carried out in a group of athletes to test the hypothesis that favourable alleles of exercise-related phenotypes are over-represented in those athletes compared to non-athletic controls (Figure 1). This approach may equally be applied to determine whether favourable alleles could be associated with direct measures of athletic capability, such as weightlifting performance, running times, or scores recorded during competitive events. In this case, the significance threshold for the second stage is set at $p < 0.05$ (to reduce the likelihood of potentially important findings being overlooked).

A recent example of such an approach being implemented is the study by Guilherme et al. [49], which investigated two correlated phenotypes: brisk walking pace (using UK Biobank participants) and sprint athlete status (using elite Russian sprinters). Brisk walkers perform more physical activity, are taller, have reduced adiposity and demonstrate greater physical performance and strength versus slower walkers, with such traits also recorded more commonly in sprinters than other athletes of other disciplines. Therefore, it was hypothesized that the alleles associated with high-speed walking (discovered in untrained subjects) would also be over-represented in elite sprinters. Accordingly, 70 genetic markers of brisk walking were identified from the literature [38], of which 15 SNPs had a significantly different allele frequency when comparing sprinters with non-athletic con-

trols [49]. The same innovative approach later identified 23 SNPs associated with strength athlete status [51] based on genome-wide significant markers for handgrip strength in a non-athletic population using the UK Biobank [34,35]. Furthermore, using a panel of 822 testosterone-related SNPs from the UK Biobank study [33], five DNA-polymorphisms associated with muscle fibre size and weightlifting performance were identified [50].




Figure 1. Case-control study designs in sports genomics. In this approach, allelic frequencies are compared between athletes and controls (e.g., endurance athletes vs. untrained subjects or endurance vs. power athletes). A case-control study may be the first step followed by a genotype–phenotype study (e.g., identification of VO_{2max} or weightlifting performance-increasing genotypes among athletes). In some cases, studies begin with a genotype–phenotype approach, and the findings are subsequently validated by a case-control study.

Another approach that has proven effective in addressing the possibility of false positive results in sports genomics literature is to perform replication studies in two or more independent athletic cohorts (even with small or moderate sample sizes), followed by a meta-analysis to quantify the overall effect of a polymorphism on athlete status and/or a sport- and exercise-related trait [43,52–65]. However, in some cases, replication is not possible due to the exclusivity of a polymorphism to specific populations based on their geographic ancestry. For example, the rs671 G/A polymorphism of the aldehyde dehydrogenase 2 (*ALDH2*) gene was associated with strength in athletes and non-athletes from the Japanese population [66–68]. Interestingly, the unfavourable (associated with reduced strength) rs671 A allele is not present in Europeans or South Asians (frequency 0%), but common in Chinese, Japanese, and Vietnamese populations (15–25%). This demonstrates a notable challenge seeking to replicate genomic findings in larger samples, as increasing the study sample must also consider the geographic ancestry of participants. This also highlights the possibility that the genetic determinants of some sport- and exercise-related phenotypes are restricted to certain populations, demonstrating that increasing sample size is not as straightforward as simply recruiting participants from multiple countries and/or continents.

As well as the phenotypes of athlete status or competitive performance, several recent studies have investigated a broader range of traits which may relate directly or indirectly to athletic capability. These include flexibility, coordination, cardiorespiratory fitness, spatial ability, stress resilience, mental toughness, fat loss efficiency, and cardiovascular and metabolic responses to training, amongst others [69–84]. For example, combat athletes are more likely than untrained subjects to have the warrior (*COMT* rs4680 GG) genotype [85], whilst chess players demonstrate an increased frequency of an allele linked to improved memory and spatial ability (*KIBRA* rs17070145 T) [86]. Such discoveries demonstrate the broadening nature of sports genomics in recent times, with focus expanding from the traditional domain of investigating what makes elite performers different from the general population into other domains, such as sports nutrigenetics [87–100] and areas of sports medicine, such as genomic variants associated with soft-tissue injuries and sports-related concussion [101–114].

Technological advancement has lowered the cost of conducting genomic studies, increasing accessibility to researchers who wish to investigate the genetic underpinnings of sport and exercise phenotypes. Consequently, sports genomics is a dynamic and continually developing field, making it important to regularly appraise the contribution of recent advances to the field. Therefore, the aim of the current review was to summarise recent progress in understanding the genetic determinants of athlete status, and to detail novel DNA polymorphisms that may underpin differences between individuals in their athletic potential.

At the time of writing (end of May 2023), the total number of DNA polymorphisms associated with athletic performance since the first discovery in 1998 is 251 (Figure 2). Our search for sports genomics publications was based on journals indexed in major databases (i.e., PubMed etc.) using specific key words (e.g., athletes + polymorphism/genotype etc.). However, not all articles were included in the current review due to language limitations (articles written in languages other than English must contain at least abstracts in English). In addition, papers with very small cohort (less than 25 in athletes/controls), or articles with combined groups of athletes (for example, endurance + power without separation) were not included. Abstracts of conference proceedings were not considered. In recognition of the fact that many studies in the field of sports genomics report associations based on the investigation of small sample sizes, we stipulated that only markers where statistically significant associations have been reported in at least two studies (two case-control studies and/or one case-control plus one functional study; including those presented in one article) would be included in the present review.




Figure 2. Sports-related genetic markers discovered between 1998 and 2023.

According to these criteria, 128 markers could be associated with athlete status (41 endurance-related, 45 power-related, and 42 strength-related) from the original 251 identified in our literature search. The most promising genetic markers (i.e., most replicated

and had fewer negative or controversial findings) include *AMPD1* rs17602729 C, *CDKN1A* rs236448 A, *HFE* rs1799945 G, *MYBPC3* rs1052373 G, *NFIA-AS2* rs1572312 C, *PPARA* rs4253778 G, and *PPARGC1A* rs8192678 G alleles for endurance; *ACTN3* rs1815739 C, *AMPD1* rs17602729 C, *CDKN1A* rs236448 C, *CPNE5* rs3213537 G, *GALNTL6* rs558129 T, *IGF2* rs680 G, *IGSF3* rs699785 A, *NOS3* rs2070744 T, and *TRHR* rs7832552 T alleles for power; and *ACTN3* rs1815739 C, *AR* ≥ 21 CAG repeats, *LRPPRC* rs10186876 A, *MMS22L* rs9320823 T, *PHACTR1* rs6905419 C, and *PPARG* rs1801282 G alleles for strength. This update on the panel of genetic markers associated with athlete status covers advances in research reported in the past two years (previous online version was published in 2021 [115]). The current review also lists all known markers associated with endurance, power, or strength athlete status/performance. This article does not aim to review genetic markers associated with team (game) and combat sports, markers for which are well described elsewhere [26,61,116,117].

2. Gene Variants for Endurance Athlete Status

An individual's endurance capacity is determined by many factors, including their muscle fibre typology, haemoglobin mass, mitochondrial biogenesis, maximal cardiac output, and maximal rate of oxygen consumption (VO_{2max}), among others [118–124]. Indeed, there is evidence that these intermediate phenotypes have a substantial genetic influence, with literature indicating that genetic factors account for up to 70% of the variability in endurance-related traits [125]. Usually, genetic markers associated with endurance athlete status are determined by comparing allelic frequencies between endurance athletes (e.g., biathletes, road cyclists etc.) and controls.

To support the observed findings from endurance-related case-control studies, researchers subsequently perform functional, lab-based studies to determine the relationship between genotypes and physiological measures. Examples of measurements used to complement genomic studies include (but are not limited to) VO_{2max} , forced expiratory volume in one second (FEV1), proportion of slow-twitch muscle fibres, recovery speed, long-distance running performance, running economy, lactate threshold, erythropoietin and haemoglobin levels, number of erythrocytes, capillary density, mitochondrial density, fat metabolism, and fatigue resistance.

Our literature search revealed that at least 41 of the 114 reported markers could be associated with endurance athlete status based on our criteria (Table 1). The most promising genetic markers for endurance athlete status include *AMPD1* rs17602729 C, *CDKN1A* rs236448 A, *HFE* rs1799945 G, *MYBPC3* rs1052373 G, *NFIA-AS2* rs1572312 C, *PPARA* rs4253778 G, and *PPARGC1A* rs8192678 G alleles. In contrast, the other 73 markers (endurance alleles) have not passed our strict criteria: *ACOXL* rs13027870 G, *ADRA2A* 6.7kb, *ADRA2A* rs1800544 G, *ADRB1* rs1801252 G, *AGT* rs699 A, *BDKRB2* rs1799722 T, *CAMK1D* rs11257754 A, *CHRN3* rs4950 G, *CLSTN2* rs2194938 A, *CNDP2* rs6566810 A, *COL5A1* rs71746744 AGGG, *COL6A1* rs35796750 T, *CPQ* rs6468527 A, *CYP2D6* rs3892097 G, *DMT1* 258 bp, *EPAS1 (HIF2A)* rs1867785 G, *EPAS1 (HIF2A)* rs11689011 T, *GABPB1* rs8031031 T, *GALM* rs3821023 A, *GNB3* rs5443 T, *GRM3* rs724225 G, *GSTT* rs17856199 (+), *IGF1R* rs1464430 A, *IL6* rs1800795 C, *IL15RA* rs2228059 A, *ITPR1* rs1038639 T, *ITPR1* rs2131458 T, *FMNL2* rs12693407 G, *KCNJ11* rs5219 C, *L3MBTL4* rs17483463 T, *MSTN* rs11333758 D, MtdNA loci (G1, HV, L0, M*, m.11215T, m.152C, m.15518T, m.15874G, m.4343G, m.514(CA) ≤ 4 , poly(C ≥ 7) stretch at m.568–573, m.16080G, m.5178C, N9, V, unfavourable: B, J2, T, L3*), *NALCN-AS1* rs4772341 A, *NACC2* rs4409473 C, *NATD1* rs732928 G, *NOS3* rs1799983 G, *NOS3 (CA)n* 164bp, *NOS3* 27bp 4B, *PPARD* rs2016520 C, *PPARD* rs1053049 T, *PPARGC1A* rs4697425 A, *PPARGC1B* rs11959820 A, *PPP3CA* rs3804358 C, *PPP3CB* rs3763679 C, *SGMS1* rs884880 A, *SLC2A4* rs5418 A, *SOD2* rs4880 C, *SPOCK1* rs1051854 T, *TPK1* rs10275875 T, *TTN* rs10497520 T, Y-chromosome haplogroups (E*, E3*, and K*(xP); unfavourable: E3b1), and *ZNF429* rs1984771 G. Most of these markers have been described in previous reviews [27,126,127] but cannot be included in our current list of endurance-associated markers until they are validated through replication by additional studies.

Table 1. Genetic markers for endurance athlete status.

Gene	Full Name	Locus	Polymorphism	Endurance-Related Allele	References	
					Studies with Positive Results	Studies with Negative or Controversial Results
<i>ACE</i>	Angiotensin I converting enzyme	17q23.3	Alu I/D (rs4343 A/G or rs4341 C/G)	I (A or C)	[14–16,128–141]	[133,142–153]
<i>ACTN3</i>	Actinin α 3	11q13.1	rs1815739 C/T	T	[17,154–156]	[152,157–170]
<i>ADRB2</i>	Adrenoceptor β 2	5q31-q32	rs1042713 G/A	A	[160,171,172]	[173,174]
<i>ADRB2</i>	Adrenoceptor β 2	5q31-q32	rs1042714 G/C	C	[153,175]	[173,174]
<i>ADRB3</i>	Adrenoceptor β 3	8p11.23	rs4994 A/G	G	[170,173]	
<i>AGTR2</i>	Angiotensin II receptor type 2	Xq22-q23	rs11091046 A/C	C	[176]	[177]
<i>AQP1</i>	Aquaporin 1	7p14	rs1049305 C/G	C	[178–180]	
<i>AMPD1</i>	Adenosine monophosphate deaminase 1	1p13	rs17602729 C/T	C	[19,153,181–183]	[184]
<i>BDKRB2</i>	Bradykinin receptor B2	14q32.1-q32.2	+9/−9 (exon 1)	−9	[185,186]	[153,187–189]
<i>CDKN1A</i>	Cyclin Dependent Kinase Inhibitor 1A	6p21.2	rs236448 A/C	A	[43]	
<i>CKM</i>	Creatine kinase M-type	19q13.32	rs8111989 A/G	A	[190–192]	[133,193]
<i>COL5A1</i>	Collagen type V α 1 chain	9q34.2-q34.3	rs12722 C/T	T	[194,195]	
<i>FTO</i>	FTO α -Ketoglutarate Dependent Dioxygenase	16q12.2	rs9939609 T/A	T	[196,197]	[198]
<i>GABPB1</i>	GA binding protein transcription factor subunit β 1	15q21.2	rs12594956 A/C	A	[199,200]	
			rs7181866 A/G	G	[199,201]	[200]
<i>GALNTL6</i>	Polypeptide N-acetylgalactosaminyltransferase 6	4q34.1	rs558129 T/C	C	[40]	
<i>GSTP1</i>	Glutathione S-transferase Pi 1	11q13.2	rs1695 A/G	G	[202,203]	
<i>HFE</i>	Homeostatic iron regulator	6p21.3	rs1799945 C/G	G	[153,204–207]	
<i>HIF1A</i>	Hypoxia inducible factor 1 subunit α	14q23.2	rs11549465 C/T	C	[208,209]	[144,210]

Table 1. Cont.

Gene	Full Name	Locus	Polymorphism	Endurance-Related Allele	References	
					Studies with Positive Results	Studies with Negative or Controversial Results
<i>MCT1</i>	Monocarboxylate transporter 1	1p12	rs1049434 A/T	T	[60,211–214]	[215]
MtDNA loci	Mitochondrial DNA	MtDNA	MtDNA haplogroups	H	[161,216]	
				Unfavourable: K	[161,216]	
<i>MYBPC3</i>	Myosin Binding Protein C3	11p11.2	rs1052373 A/G	G	[42]	
<i>NFATC4</i>	Nuclear factor of activated T cells 4	14q11.2	rs2229309 G/C	G	[144]	
<i>NFIA-AS2</i>	NFIA antisense RNA 2	1p31.3	rs1572312 C/A	C	[39,46]	
<i>NOS3</i>	Nitric oxide synthase 3	7q36	rs2070744 T/C	T	[153,217,218]	[219]
<i>PPARA</i>	Peroxisome proliferator activated receptor α	22q13.31	rs4253778 G/C	G	[20,220–222]	
<i>PPARGC1A</i>	Peroxisome proliferative activated receptor, γ , coactivator 1 α	4p15.1	rs8192678 G/A	G	[18,20,170,223]	[216,224,225]
<i>PPARGC1B</i>	Peroxisome proliferative activated receptor, γ , coactivator 1 β	5q32	rs7732671 G/C	C	[144,226]	
<i>PPP3R1</i>	Protein phosphatase 3 regulatory subunit B, α	2p15	Promoter 5I/5D	5I	[144,227]	
<i>PRDM1</i>	PR/SET Domain 1	6q21	rs10499043 C/T	T	[228,229]	
<i>RBFOX1</i>	RNA binding fox-1 homolog 1	16p13.3	rs7191721 G/A	G	[39]	
<i>SIRT1</i>	Sirtuin 1	10q21.3	rs41299232 C/G	G	[45]	
<i>SPEG</i>	Striated Muscle Enriched Protein Kinase	2q35	rs7564856 G/A	G	[230]	
<i>TFAM</i>	Transcription factor A, mitochondrial	10q21	rs1937 G/C	C	[144,231]	[216]
<i>TRPM2</i>	Transient Receptor Potential Cation Channel Subfamily M Member 2	21q22.3	rs1785440 A/G	G	[45]	

Table 1. Cont.

Gene	Full Name	Locus	Polymorphism	Endurance-Related Allele	References	
					Studies with Positive Results	Studies with Negative or Controversial Results
<i>TSHR</i>	Thyroid stimulating hormone receptor	14q31	rs7144481 T/C	C	[39]	
<i>UCP2</i>	Uncoupling protein 2	11q13	rs660339 C/T	T	[130,144,232]	
<i>UCP3</i>	Uncoupling Protein 3	11q13	rs1800849 C/T	T	[130,144]	[233]
<i>VEGFA</i>	Vascular endothelial growth factor A	6p12	rs2010963 G/C	C	[144,234,235]	
<i>VEGFR2</i>	Vascular endothelial growth factor receptor 2	4q11-q12	rs1870377 T/A	A	[236,237]	

3. Gene Variants for Power Athlete Status

Several characteristics are positively associated with power performance, including circulating levels of testosterone, percentage and cross-sectional area of fast-twitch muscle fibres, muscle mass and strength, body and calcaneus height, muscle fascicle length, and reaction time, among others [3,238–244]. The heritability of power-related phenotypes has been reported in the literature to range from approximately 49 to 86% in a range of phenotypes, including jumping ability [245,246]. Typically, genetic markers associated with power athlete status are determined by comparing allelic frequencies between power athletes (e.g., 100 m runners, shot putters, arm wrestlers, etc.) and untrained subjects. To support findings from case-control studies, investigators perform genotype–phenotype studies by measuring sprint times, jump performance, muscle fibre size, muscle fibre typology, maximal strength, rate of force development, and circulatory levels of anabolic hormones such as testosterone. Our literature search revealed that at least 45 of the 95 markers reportedly associated with power athlete status met our new criteria (Table 2). The most promising of these genetic markers associated with power athlete status currently include *ACTN3* rs1815739 C, *AMPD1* rs17602729 C, *CDKN1A* rs236448 C, *CPNE5* rs3213537 G, *GALNTL6* rs558129 T, *IGF2* rs680 G, *IGSF3* rs699785 A, *NOS3* rs2070744 T, and *TRHR* rs7832552 T alleles. In contrast, the remaining 50 genetic markers (power alleles) did not meet our strict criteria: *ARHGEF28* rs17664695 G, *CACNG1* rs1799938 A, *CALCR* rs17734766 G, *CLSTN2* rs2194938 C, *CNDP1* rs2887 A, *CNDP1* rs2346061 C, *CNDP2* rs3764509 G, *COTL1* rs7458 T, *CREM* rs1531550 A, *DMD* rs939787 T, *EPAS1 (HIF2A)* rs1867785 G, *EPAS1 (HIF2A)* rs11689011 C, *FOCAD* rs17759424 C, *GABRR1* rs282114 A, *GALNT13* rs10196189 G, *GPC5* rs852918 T, *IGF1R* rs1464430 C, *IL1RN* rs2234663 *2, *IP6K3* rs6942022 C, *MCT1* rs1049434 A, *MED4* rs7337521 T, *MPRIP* rs6502557 A, MtDNA loci (favourable: F, m.204C, m.151T, m.15314A, Non-L/U6, unfavourable: m.16278T, m.5601T, m.4833G, m.5108C, m.7600A, m.9377G, m.13563G, m.14200C, m.14569A), *MTR* rs1805087 G, *MTRR* rs1801394 G, *NOS3* rs1799983 G, *NRG1* rs17721043 A, *PPARGC1A* rs8192678 A, *PPARGC1B* rs10060424 C, *RC3H1* rs767053 G, *SLC6A2* rs1805065 C, *SUCLA2* rs10397 A, *TPK1* rs10275875 C, *UCP2* rs660339 C, *VEGFR2* rs1870377 T, *WAPL* rs4934207 C, and *ZNF423* rs11865138 C. The majority of these markers are reported in previous reviews [25,126,127] and should be validated in additional studies before they can meet the criteria to be included in our list of power-associated genetic variants.

Table 2. Genetic markers for power athlete status.

Gene	Full Name	Locus	Polymorphism	Power-Related Allele	References	
					Studies with Positive Results	Studies with Negative or Controversial Results
<i>ACE</i>	Angiotensin I converting enzyme	17q23.3	Alu I/D (rs4343 A/G or rs4341 C/G)	D (G)	[16,128,145,169,247–250]	[150,251–254]
<i>ACVR1B</i>	Activin A type IB receptor	12q13.13	rs2854464 A/G	A	[255,256]	[256,257]
<i>ACTN3</i>	Actinin α 3	11q13.1	rs1815739 C/T	C	[17,161,162,168,170,250,258–264]	[159,165,254,265,266]
<i>ADAM15</i>	ADAM Metallopeptidase Domain 15	1q21.3	rs11264302 G/A	G	[49]	
<i>ADRB2</i>	Adrenoceptor β 2	5q31-q32	rs1042713 G/A	G	[41,174]	
			rs1042714 C/G	G	[41,174]	
<i>AGRN</i>	Agrin	1p36.33	rs4074992 C/T	C	[45]	
<i>AGT</i>	Angiotensinogen	1q42.2	rs699 T/C	C	[41,267,268]	
<i>AGTR2</i>	Angiotensin II receptor type 2	Xq22-q23	rs11091046 A/C	A	[176,177]	[55]
<i>AKAP6</i>	A-Kinase Anchoring Protein 6	14q12	rs12883788 C/T	C	[49]	
<i>AMPD1</i>	Adenosine monophosphate deaminase 1	1p13	rs17602729 C/T	C	[184,269,270]	
<i>AUTS2</i>	Activator of Transcription and Developmental Regulator AUTS2	7q11.22	rs10452738 A/G	A	[49]	
<i>BDNF</i>	Brain derived neurotrophic factor	11p14.1	rs10501089 G/A	A	[271]	
<i>CCT3</i>	Chaperonin Containing TCP1 Subunit 3	1q22	rs11548200 T/C	T	[49]	
<i>CDKN1A</i>	Cyclin Dependent Kinase Inhibitor 1A	6p21.2	rs236448 A/C	C	[43]	
<i>CKM</i>	Creatine kinase, M-type	19q13.32	rs8111989 A/G	G	[65,272,273]	[274]
<i>CNTFR</i>	Ciliary neurotrophic factor receptor	9p13.3	rs41274853 C/T	T	[275]	

Table 2. Cont.

Gene	Full Name	Locus	Polymorphism	Power-Related Allele	References	
					Studies with Positive Results	Studies with Negative or Controversial Results
<i>CPNE5</i>	Copine V	6p21.2	rs3213537 G/A	G	[41,48]	
<i>CRTAC1</i>	Cartilage Acidic Protein 1	10q24.2	rs2439823 A/G	A	[49]	
<i>CRTC1</i>	CREB Regulated Transcription Coactivator 1	19p13.11	rs11881338 T/A	A	[49]	
<i>E2F3</i>	E2F Transcription Factor 3	6p22.3	rs4134943 C/T	T	[49]	
<i>FHL2</i>	Four and a Half LIM Domains 2	2q12.2	rs55680124 C/T	C	[49]	
<i>GALNTL6</i>	Polypeptide N-acetylgalactosaminyltransferase like 6	4q34.1	rs558129 C/T	T	[47,276]	
<i>GDF5</i>	Growth Differentiation Factor 5	20q11.22	rs143384 A/G	G	[49]	
<i>HIF1A</i>	Hypoxia inducible factor 1 α subunit	14q21-q24	rs11549465 C/T	T	[277–279]	
<i>HSD17B14</i>	Hydroxysteroid 17- β dehydrogenase 14	19q13.33	rs7247312 A/G	G	[41]	
<i>IGF1</i>	Insulin like growth factor 1	12q23.2	rs35767 C/T	T	[280,281]	
<i>IGF2</i>	Insulin like growth factor 2	11p15.5	rs680 A/G	G	[41,281,282]	
<i>IGSF3</i>	Immunoglobulin Superfamily Member 3	1p13.1	rs699785 G/A	A	[49]	
<i>IL6</i>	Interleukin 6	7p21	rs1800795 C/G	G	[41,283,284]	
<i>ILRUN</i>	Inflammation and Lipid Regulator with UBA-Like and NBR1-Like Domains	6p21.31	rs205262 A/G	A	[49]	
<i>MTHFR</i>	Methylenetetrahydrofolate reductase	1p36.3	rs1801131 A/C	C	[285,286]	
<i>NOS3</i>	Nitric oxide synthase 3	7q36	rs2070744 T/C	T	[219,279,287]	

Table 2. Cont.

Gene	Full Name	Locus	Polymorphism	Power-Related Allele	References	
					Studies with Positive Results	Studies with Negative or Controversial Results
<i>NRXN3</i>	Neurexin 3	14q24.3-q31.1	rs8011870 G/A	G	[49]	
<i>NUP210</i>	Nucleoporin 210	3p25.1	rs2280084 C/A	C	[45]	
<i>PIEZO1</i>	Piezo Type Mechanosensitive Ion Channel Component 1	16q24.3	rs572934641 (TCC/-) E756del	D	[288]	
<i>PPARA</i>	Peroxisome proliferator activated receptor α	22q13.31	rs4253778 G/C	C	[159,220,289]	
<i>PPARG</i>	Peroxisome proliferator activated receptor γ	3p25.2	rs1801282 C/G	G	[279,290,291]	[292]
			rs2920503 C/T	T	[49]	
<i>SLC39A8</i>	Solute Carrier Family 39 Member 8	4q24	rs13107325 C/T	C	[49]	
<i>SOD2</i>	Superoxide dismutase 2	6q25.3	rs4880 C/T	C	[293]	
<i>TRHR</i>	Thyrotropin releasing hormone receptor	8q23.1	rs7832552 C/T	T	[65,294,295]	
<i>UBR5</i>	Ubiquitin Protein Ligase E3 Component N-Recognin 5	8q22.3	rs10505025 G/A	A	[296]	
			rs4734621 G/A	A	[296]	
<i>ZNF568</i>	Zinc Finger Protein 568	19q13.12	rs1667369 A/C	A	[49]	

4. Gene Variants for Strength Athlete Status

Performance in strength-based sports is based on multiple factors. However, the factors considered to contribute substantially to strength phenotypes include skeletal muscle hypertrophy (muscle fibre size), hyperplasia, the predominance of fast-twitch muscle fibres, a greater muscle fascicle pennation angle, improved neurological adaptation, high glycolytic capacity, and increased circulatory testosterone [297]. Importantly, evidence exists that strength athletes exhibit vastly different transcriptomic, biochemical, anthropometric, physiological, and biomechanical characteristics compared to endurance athletes and/or controls [1,4]. These differences can be explained by the presence of both deliberate environmental (training, nutrition, etc.) and genetic factors. Indeed, studies indicate that there is a strong heritability of power- and strength-related traits, where genetic factors account for up to 85% of the variation in maximal isometric, isotonic, and isokinetic strength [246]. In a recent study investigating the genetic component of severe sarcopenia (the age-related decline in skeletal muscle mass, strength, and gait speed) [37], it was found that the alleles associated with higher risk of severe sarcopenia were closely linked to tiredness, alcohol intake, smoking, time spent watching television, and a higher self-reported consumption of salt and processed meat. In contrast, alleles associated with lower risk of severe sarcopenia were positively associated with levels of serum testosterone, IGF1, and 25-hydroxyvitamin D; height; physical activity; as well as indicators of healthier dietary habits (self-reported intake of cereal, cheese, oily fish, protein, water, fruit, and vegetables). Whilst muscle strength phenotypes in the general population may be less pronounced than in strength athletes, the latter may represent an ideal population to identify genomic variants associated with skeletal muscle capacity, potentially aiding the advancement of knowledge surrounding sarcopenia and directing strategies to reduce the negative impact of age-related declines in muscle mass. In general, genetic markers associated with strength athlete status can be determined by comparing allelic frequencies between strength athletes and controls. To support these findings, scientists perform genotype–phenotype studies by measuring handgrip and isokinetic strength, powerlifting/weightlifting performance, as well as evaluating the acute and chronic responses to resistance training.

Previously, 170 DNA polymorphisms were reported to be associated with handgrip strength in three large GWASs [34–36]. In a follow-up study involving elite weightlifters and powerlifters, Moreland et al. [51] tested the hypothesis that alleles associated with greater handgrip strength would be over-represented in these athletes compared to controls. Accordingly, they identified 23 DNA polymorphisms that were associated with strength athlete status. Of these SNPs, the *LRPPRC* rs10186876, *MMS22L* rs9320823, and *PHACTR1* rs6905419 polymorphisms were also associated with superior competitive weightlifting performance [298].

Our literature search based on our new inclusion criteria revealed that at least 42 genetic markers could be associated with strength athlete status (Table 3). The most promising genetic markers for strength athlete status include *ACTN3* rs1815739 C, *AR* ≥ 21 CAG repeats, *LRPPRC* rs10186876 A, *MMS22L* rs9320823 T, *PHACTR1* rs6905419 C, and *PPARG* rs1801282 G alleles.

Table 3. Genetic markers for strength athlete status.

Gene	Full Name	Locus	Polymorphism	Strength-Related Allele	References	
					Studies with Positive Results	Studies with Negative or Controversial Results
<i>ABHD17C</i>	Abhydrolase domain containing 17C	15q25.1	rs7165759 G/A	A	[35,51]	
<i>ACE</i>	Angiotensin I converting enzyme	17q23.3	Alu I/D (rs4343 A/G or rs4341 C/G)	D (G)	[299–304]	[305]
<i>ACTG1</i>	Actin γ 1	17q25.3	rs6565586 T/A	A	[34,51]	
<i>ACTN3</i>	Actinin α 3	11q13.1	rs1815739 C/T	C	[302,306–308]	[51,305,309,310]
<i>ADCY3</i>	Adenylate cyclase 3	2p23.3	rs10203386 T/A	T	[35,51]	
<i>ADPGK</i>	ADP dependent glucokinase	15q24.1	rs4776614 C/G	C	[35,51]	
<i>AGT</i>	Angiotensinogen	1q42.2	rs699 T/C	C	[310,311]	[51]
<i>ALDH2</i>	Aldehyde Dehydrogenase 2 Family Member	12q24.12	rs671 G/A	G	[66–68]	
<i>ANGPT2</i>	Angiotensin II type 2 receptor 2	8p23.1	rs890022 G/A	A	[51,312]	
<i>AR</i>	Androgen Receptor	Xq12	(CAG) _n	≥ 21	[313,314]	
<i>ARPP21</i>	CAMP regulated phosphoprotein 21	3p22.3	rs1513475 T/C	C	[35,51]	
<i>BCDIN3D</i>	Bicoid interacting 3 domain containing RNA methyltransferase	12q13.12	rs12367809 C/T	C	[35,51]	
<i>CKM</i>	Creatine kinase, M-type	19q13.32	rs8111989 A/G	G	[54,315]	[51,274]
<i>CNTFR</i>	Ciliary neurotrophic factor receptor	9p13.3	rs41274853 C/T	T	[275,316]	[51]
<i>CRTAC1</i>	Cartilage acidic protein 1	10q24.2	rs563296 G/A	G	[35,51]	
<i>DHODH</i>	Dihydroorotate dehydrogenase (Quinone)	16q22.2	rs12599952 G/A	A	[35,51]	
<i>GALNTL6</i>	Polypeptide N-acetylgalactosaminyltransferase-like 6	4q34.1	rs558129 C/T	T	[47]	
<i>GBE1</i>	1, 4- α -glucan branching enzyme 1	3p12.2	rs9877408 A/G	A	[35,51]	
<i>GBF1</i>	Golgi brefeldin A resistant guanine nucleotide exchange factor 1	10q24.32	rs2273555 G/A	A	[34,317]	

Table 3. Cont.

Gene	Full Name	Locus	Polymorphism	Strength-Related Allele	References	
					Studies with Positive Results	Studies with Negative or Controversial Results
<i>GLIS3</i>	GLIS Family Zinc Finger 3	9p24.2	rs34706136 T/TG	TG	[50]	
<i>HIF1A</i>	Hypoxia inducible factor 1 α	14q21-q24	rs11549465 C/T	T	[278,295,318]	[51]
<i>IGF1</i>	Insulin-like growth factor 1	12q23.2	rs35767 C/T	T	[51,280,319]	
<i>IL6</i>	Interleukin 6	7p21	rs1800795 C/G	G	[51,283]	
<i>ITPR1</i>	Inositol 1, 4, 5-Triphosphate Receptor Type 1	3p26.1	rs901850 G/T	T	[35,51]	
<i>KIF1B</i>	Kinesin family member 1B	1p36.22	rs11121542 G/A	G	[35,51]	
<i>LRPPRC</i>	Leucine-rich pentatricopeptide repeat cassette	2p21	rs10186876 A/G	A	[34,51,298]	
<i>MLN</i>	Motilin	6p21.31	rs12055409 A/G	G	[35,317]	
<i>MMS22L</i>	Methyl methanesulfonate-sensitivity protein 22-Like	6q16.1	rs9320823 T/C	T	[35,51,298]	
<i>MTHFR</i>	Methylenetetrahydrofolate reductase	1p36.3	rs1801131 A/C	C	[51,286,298]	
<i>NPIP6</i>	Nuclear pore complex interacting protein family member B6	16p12.1	rs2726036 A/C	A	[35,51]	
<i>PHACTR1</i>	Phosphate and actin regulator 1	6p24.1	rs6905419 C/T	C	[35,51,298]	
<i>PLEKHB1</i>	Pleckstrin homology domain containing B1	11q13.4	rs7128512 A/G	G	[51,312]	
<i>PPARA</i>	Peroxisome proliferator activated receptor α	22q13.31	rs4253778 G/C	C	[220,320,321]	[51]
<i>PPARG</i>	Peroxisome proliferator activated receptor γ	3p25.2	rs1801282 C/G	G	[51,290,291]	
<i>PPARGC1A</i>	Peroxisome proliferative activated receptor, γ , coactivator 1 α	4p15.2	rs8192678 G/A	A	[51,305,308]	
<i>R3HDM1</i>	R3H domain containing 1	2q21.3	rs6759321 G/T	T	[35,51]	
<i>RASGRF1</i>	Ras protein specific guanine nucleotide Releasing Factor 1	15q25.1	rs1521624 C/A	A	[35,51]	

Table 3. Cont.

Gene	Full Name	Locus	Polymorphism	Strength-Related Allele	References	
					Studies with Positive Results	Studies with Negative or Controversial Results
<i>RMC1</i>	Regulator of MON1-CCZ1	18q11.2	rs303760 C/T	C	[35,51]	
<i>SLC39A8</i>	Solute carrier family 39 member 8	4q24	rs13135092 A/G	A	[35,51]	
<i>TFAP2D</i>	Transcriptional factor AP-2 delta	6p12.3	rs56068671 G/T	T	[35,51]	
<i>ZKSCAN5</i>	Zinc finger with KRAB and SCAN domains 5	7q22.1	rs3843540 T/C	C	[35,51]	
<i>ZNF608</i>	Zinc finger protein 608	5q23.2	rs4626333 G/A	G	[312,317]	

5. Conclusions

The current review demonstrates that at least 251 genetic markers are reportedly linked to sport-related traits. However, only 128 (51%) of these markers (41 endurance-related, 45 power-related, and 42 strength-related) have been associated with athlete status in two or more studies. On the other hand, of these 128 genetic markers, the significance of 29 (22.7%) DNA polymorphisms was not replicated in at least one study, raising the possibility that a number of findings may represent false positives. It is important to consider that there may be one of several reasons why the findings of a study may not be replicated by another, including disparity of sample sizes, small sample sizes in one or more of the studies, different study designs, inconsistent classification of sporting groups or types of sport (strength, power, etc.), variability in how researchers or research groups define the term “elite athletes” (some researchers define the term “elite” as performances at the international level, others if the athlete is a prize winner in international competitions), and the ethnicity/geographical ancestry of the cohorts studied, amongst others.

As discussed previously, height remains not only the most studied exercise-related phenotype at the genetic level, but also the most studied human trait, with 12,111 associated SNPs [31]. It is estimated that the final number of height-related SNPs may reach 25,000 (with a minor allele frequency of $\geq 1\%$), but the sample size needs to be increased to approximately 100 million individuals of the same ethnicity. These values should be noteworthy and serve as a benchmark for the direction of future research in the field of sports genomics, where the current number of 251 genetic markers must be increased by a considerable magnitude in order to fully comprehend the genomic underpinnings of exercise performance, and thus to be considered as potential predictors of talent in sport. Given that effective talent identification remains a challenging task despite decades of research and strategy [322–324], it remains possible that the development of predictive genetic performance tests in future may be able to contribute to the advancement of this field. However, the literature currently available does not support the use of genetic testing for these purposes [325–327].

Whilst genomics is the among the most established molecular sub-disciplines of sport and exercise research, sport- and exercise-related DNA polymorphisms do not fully explain the heritability of athlete status. Consequently, other forms of variation, such as rare mutations [328,329] and epigenetic markers (i.e., stable and heritable changes in gene expression) [330], must be considered. Newly emerging high-throughput technologies enable the design of multi-omics approaches integrating various -omics levels (metabolomics, transcriptomics, proteomics, epigenomics, etc.) with the aim of determining how each level contributes to the biological mechanisms underpinning physical performance. For example, transcriptomic analyses have revealed the roles of both genomic and epigenomic mechanisms in modulating the transcription of genes regulated by exercise [2,331,332]. Incorporating multi-omics approaches has the potential to drastically advance the understanding of how the acute response to exercise is regulated, and consequently how chronic adaptations to exercise are mediated in the context of elite performance and/or health and wellbeing. Accordingly, future research, including collaborative multicentre GWASs and whole-genome sequencing of large athlete cohorts with further validation and replication, as well as the use of large purpose-built Biobanks, should focus on identifying genetic and other -omics markers of sport-related phenotypes and their underlying biology.

Our review does have limitations. First, we have not provided information regarding genetic markers associated with team (game) and combat sports, flexibility, coordination, personality, cognitive abilities, muscle fibre composition, skeletal muscle hypertrophy, injuries, and responses to training/supplements. These markers are well described elsewhere [4,24,26,28,37,61,74,79,115–117,333,334]. Second, we have not described all studies in detail (ethnicity, specific sporting disciplines, sample size, *p*-values etc.) given word limit. Third, some genetic markers (out of the 128 most significant) were selected based on data obtained in case-control studies only, without confirmation of functional significance (genotype–phenotype studies are therefore warranted).

In conclusion, our literature search revealed at least 251 DNA polymorphisms that could be associated with endurance, power, and strength athlete statuses. Most of these genetic markers have been discovered in studies involving Australian, Brazilian, British, Canadian, Chinese, Croatian, Czech, Ethiopian, Finnish, French, German, Greek, Hungarian, Indian, Iranian, Israeli, Italian, Jamaican, Japanese, Kenyan, Korean, Lithuanian, Polish, Qatari, Russian, Slovenian, South African, Spanish, Taiwanese, Tatar, Tunisian, Turkish, Ukrainian, and US athletes.

Author Contributions: Conceptualization, I.I.A.; formal analysis, E.A.S. and I.I.A.; writing—original draft preparation, E.A.S. and I.I.A.; writing—review and editing, E.C.R.H. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Stepto, N.K.; Coffey, V.G.; Carey, A.L.; Ponnampalam, A.P.; Canny, B.J.; Powell, D.; Hawley, J.A. Global Gene Expression in Skeletal Muscle from Well-Trained Strength and Endurance Athletes. *Med. Sci. Sport. Exerc.* **2009**, *41*, 546–565. [[CrossRef](#)] [[PubMed](#)]
2. Zhelankin, A.V.; Iulmetova, L.N.; Ahmetov, I.I.; Generozov, E.V.; Sharova, E.I. Diversity and Differential Expression of MicroRNAs in the Human Skeletal Muscle with Distinct Fiber Type Composition. *Life* **2023**, *13*, 659. [[CrossRef](#)] [[PubMed](#)]
3. Ahmetov, I.I.; Stepanova, A.A.; Biktagirova, E.M.; Semenova, E.A.; Shchuplova, I.S.; Bets, L.V.; Andryushchenko, L.B.; Borisov, O.V.; Andryushchenko, O.N.; Generozov, E.V.; et al. Is testosterone responsible for athletic success in female athletes? *J. Sport. Med. Phys. Fit.* **2020**, *60*, 1377–1382. [[CrossRef](#)]
4. Fuku, N.; Kumagai, H.; Ahmetov, I.I. Genetics of muscle fiber composition. In *Sports, Exercise, and Nutritional Genomics: Current Status and Future Directions*; Barh, D., Ahmetov, I., Eds.; Academic Press: Cambridge, MA, USA, 2019; pp. 295–314. [[CrossRef](#)]
5. Hall, E.C.R.; Semenova, E.A.; Borisov, O.V.; Andryushchenko, O.N.; Andryushchenko, L.B.; Zmijewski, P.; Generozov, E.V.; Ahmetov, I.I. Association of muscle fiber composition with health and exercise-related traits in athletes and untrained subjects. *Biol. Sport* **2021**, *38*, 659–666. [[CrossRef](#)] [[PubMed](#)]
6. Rees, T.; Hardy, L.; Güllich, A.; Abernethy, B.; Côté, J.; Woodman, T.; Montgomery, H.; Laing, S.; Warr, C. The Great British Medalists Project: A Review of Current Knowledge on the Development of the World’s Best Sporting Talent. *Sport. Med.* **2016**, *46*, 1041–1058. [[CrossRef](#)]
7. Blume, K.; Wolfarth, B. Identification of Potential Performance-Related Predictors in Young Competitive Athletes. *Front. Physiol.* **2019**, *10*, 1394. [[CrossRef](#)]
8. Dines, H.R.; Nixon, J.; Lockey, S.J.; Herbert, A.J.; Kipps, C.; Pedlar, C.R.; Day, S.H.; Heffernan, S.M.; Antrobus, M.R.; Brazier, J.; et al. Collagen Gene Polymorphisms Previously Associated with Resistance to Soft-Tissue Injury Are More Common in Competitive Runners Than Nonathletes. *J. Strength Cond. Res.* **2023**, *37*, 799–805. [[CrossRef](#)]
9. De Moor, M.H.M.; Spector, T.D.; Cherkas, L.F.; Falchi, M.; Hottenga, J.J.; Boomsma, D.I.; de Geus, E.J.C. Genome-wide linkage scan for athlete status in 700 British female DZ twin pairs. *Twin Res. Hum. Genet.* **2007**, *10*, 812–820. [[CrossRef](#)]
10. Macnamara, B.N.; Hambrick, D.Z.; Oswald, F.L. Deliberate practice and performance in music, games, sports, education, and professions: A meta-analysis. *Psychol. Sci.* **2014**, *25*, 1608–1618. [[CrossRef](#)]
11. Beck, K.L.; Thomson, J.S.; Swift, R.J.; von Hurst, P.R. Role of nutrition in performance enhancement and postexercise recovery. *Open Access J. Sports Med.* **2015**, *6*, 259–267. [[CrossRef](#)]
12. Bezuglov, E.; Morgans, R.; Butovskiy, M.; Emanov, A.; Shagiakhmetova, L.; Pirmakhanov, B.; Waśkiewicz, Z.; Lazarev, A. The relative age effect is widespread among European adult professional soccer players but does not affect their market value. *PLoS ONE* **2023**, *18*, e0283390. [[CrossRef](#)]
13. Rivera, M.A.; Dionne, F.T.; Wolfarth, B.; Chagnon, M.; Simoneau, J.A.; Pérusse, L.; Boulay, M.R.; Gagnon, J.; Song, T.M.; Keul, J.; et al. Muscle-specific creatine kinase gene polymorphisms in elite endurance athletes and sedentary controls. *Med. Sci. Sport. Exerc.* **1997**, *29*, 1444–1447. [[CrossRef](#)]
14. Montgomery, H.E.; Marshall, R.; Hemingway, H.; Myerson, S.; Clarkson, P.; Dollery, C.; Hayward, M.; Holliman, D.E.; World, M.; Thomas, E.L.; et al. Human gene for physical performance. *Nature* **1998**, *393*, 221–222. [[CrossRef](#)]
15. Gayagay, G.; Yu, B.; Hambly, B.; Boston, T.; Hahn, A.; Celermajer, D.S.; Trent, R.J. Elite endurance athletes and the ACE I allele—the role of genes in athletic performance. *Hum. Genet.* **1998**, *103*, 48–50. [[CrossRef](#)]

16. Nazarov, I.B.; Woods, D.R.; Montgomery, H.E.; Shneider, O.V.; Kazakov, V.I.; Tomilin, N.V.; Rogozkin, V.A. The angiotensin converting enzyme I/D polymorphism in Russian athletes. *Eur. J. Hum. Genet.* **2001**, *9*, 797–801. [[CrossRef](#)]
17. Yang, N.; MacArthur, D.G.; Gulbin, J.P.; Hahn, A.G.; Beggs, A.H.; Easteal, S.; North, K. ACTN3 genotype is associated with human elite athletic performance. *Am. J. Hum. Genet.* **2003**, *73*, 627–631. [[CrossRef](#)]
18. Lucia, A.; Gómez-Gallego, F.; Barroso, I.; Rabadán, M.; Bandrés, F.; San Juan, A.F.; Chicharro, J.L.; Ekelund, U.; Brage, S.; Earnest, C.P.; et al. PPARGC1A genotype (Gly482Ser) predicts exceptional endurance capacity in European men. *J. Appl. Physiol.* **2005**, *99*, 344–348. [[CrossRef](#)]
19. Rubio, J.C.; Martín, M.A.; Rabadán, M.; Gómez-Gallego, F.; San Juan, A.F.; Alonso, J.M.; Chicharro, J.L.; Pérez, M.; Arenas, J.; Lucia, A. Frequency of the C34T mutation of the AMPD1 gene in world-class endurance athletes: Does this mutation impair performance? *J. Appl. Physiol.* **2005**, *98*, 2108–2112. [[CrossRef](#)]
20. Akhmetov, I.I.; Popov, D.V.; Mozhańska, I.A.; Missina, S.S.; Astratenkova, I.V.; Vinogradova, O.L.; Rogozkin, V.A. Association of regulatory genes polymorphisms with aerobic and anaerobic performance of athletes. *Russ. Fiziol. Zh. Im. I.M. Sechenova* **2007**, *93*, 837–843.
21. Akhmetov, I.I.; Astranenkova, I.V.; Rogozkin, V.A. Association of PPARD gene polymorphism with human physical performance. *Mol. Biol.* **2007**, *41*, 852–857.
22. Bray, M.S.; Hagberg, J.M.; Pérusse, L.; Rankinen, T.; Roth, S.M.; Wolfarth, B.; Bouchard, C. The human gene map for performance and health-related fitness phenotypes: The 2006–2007 update. *Med. Sci. Sports Exerc.* **2009**, *41*, 35–73. [[CrossRef](#)] [[PubMed](#)]
23. Gineviciene, V.; Utkus, A.; Pranckevičienė, E.; Semenova, E.A.; Hall, E.C.R.; Ahmetov, I.I. Perspectives in Sports Genomics. *Biomedicines* **2022**, *10*, 298. [[CrossRef](#)] [[PubMed](#)]
24. Cagnin, S.; Chemello, F.; Ahmetov, I.I. Genes and response to aerobic training. In *Sports, Exercise, and Nutritional Genomics: Current Status and Future Directions*; Barh, D., Ahmetov, I., Eds.; Academic Press: Cambridge, MA, USA, 2019; pp. 169–188. [[CrossRef](#)]
25. Maciejewska-Skrendo, A.; Sawczuk, M.; Cieszczyk, P.; Ahmetov, I.I. Genes and power athlete status. In *Sports, Exercise, and Nutritional Genomics: Current Status and Future Directions*; Barh, D., Ahmetov, I., Eds.; Academic Press: Cambridge, MA, USA, 2019; pp. 41–72. [[CrossRef](#)]
26. Massidda, M.; Calò, C.M.; Cieszczyk, P.; Kikuchi, N.; Ahmetov, I.I.; Williams, A.G. Genetics of Team Sports. In *Sports, Exercise, and Nutritional Genomics: Current Status and Future Directions*; Barh, D., Ahmetov, I., Eds.; Academic Press: Cambridge, MA, USA, 2019; pp. 105–128. [[CrossRef](#)]
27. Semenova, E.A.; Fuku, N.; Ahmetov, I.I. Genetic profile of elite endurance athletes. In *Sports, Exercise, and Nutritional Genomics: Current Status and Future Directions*; Barh, D., Ahmetov, I., Eds.; Academic Press: Cambridge, MA, USA, 2019; pp. 73–104. [[CrossRef](#)]
28. Valeeva, E.V.; Ahmetov, I.I.; Rees, T. Psychogenetics and sport. In *Sports, Exercise, and Nutritional Genomics: Current Status and Future Directions*; Barh, D., Ahmetov, I., Eds.; Academic Press: Cambridge, MA, USA, 2019; pp. 147–165. [[CrossRef](#)]
29. Varillas-Delgado, D.; Del Coso, J.; Gutiérrez-Hellín, J.; Aguilar-Navarro, M.; Muñoz, A.; Maestro, A.; Morencos, E. Genetics and sports performance: The present and future in the identification of talent for sports based on DNA testing. *Eur. J. Appl. Physiol.* **2022**, *122*, 1811–1830. [[CrossRef](#)] [[PubMed](#)]
30. Wang, G.; Tanaka, M.; Eynon, N.; North, K.N.; Williams, A.G.; Collins, M.; Moran, C.N.; Britton, S.L.; Fuku, N.; Ashley, E.A.; et al. The Future of Genomic Research in Athletic Performance and Adaptation to Training. *Genet. Sport.* **2016**, *61*, 55–67. [[CrossRef](#)]
31. Yengo, L.; Vedantam, S.; Marouli, E.; Sidorenko, J.; Bartell, E.; Sakaue, S.; Graff, M.; Eliassen, A.U.; Jiang, Y.; Raghavan, S.; et al. A saturated map of common genetic variants associated with human height. *Nature* **2022**, *610*, 704–712. [[CrossRef](#)]
32. Pei, Y.F.; Liu, Y.Z.; Yang, X.L.; Zhang, H.; Feng, G.J.; Wei, X.T.; Zhang, L. The genetic architecture of appendicular lean mass characterized by association analysis in the UK Biobank study. *Commun. Biol.* **2020**, *3*, 608. [[CrossRef](#)]
33. Ruth, K.S.; Day, F.R.; Tyrrell, J.; Thompson, D.J.; Wood, A.R.; Mahajan, A.; Beaumont, R.N.; Wittemans, L.; Martin, S.; Busch, A.S.; et al. Using human genetics to understand the disease impacts of testosterone in men and women. *Nat. Med.* **2020**, *26*, 252–258. [[CrossRef](#)]
34. Willems, S.M.; Wright, D.J.; Day, F.R.; Trajanoska, K.; Joshi, P.K.; Morris, J.A.; Matteini, A.M.; Garton, F.C.; Grarup, N.; Oskolkov, N.; et al. Large-scale GWAS identifies multiple loci for hand grip strength providing biological insights into muscular fitness. *Nat. Commun.* **2017**, *8*, 16015. [[CrossRef](#)]
35. Tikkanen, E.; Gustafsson, S.; Amar, D.; Shcherbina, A.; Waggott, D.; Ashley, E.A.; Ingelsson, E. Biological Insights into Muscular Strength: Genetic Findings in the UK Biobank. *Sci. Rep.* **2018**, *8*, 6451. [[CrossRef](#)]
36. Jones, G.; Trajanoska, K.; Santanasto, A.J.; Stringa, N.; Kuo, C.L.; Atkins, J.L.; Lewis, J.R.; Duong, T.; Hong, S.; Biggs, M.L.; et al. Genome-wide meta-analysis of muscle weakness identifies 15 susceptibility loci in older men and women. *Nat. Commun.* **2021**, *12*, 654. [[CrossRef](#)]
37. Semenova, E.A.; Pranckevičienė, E.; Bondareva, E.A.; Gabdrakhmanova, L.J.; Ahmetov, I.I. Identification and Characterization of Genomic Predictors of Sarcopenia and Sarcopenic Obesity Using UK Biobank Data. *Nutrients* **2023**, *15*, 758. [[CrossRef](#)]
38. Timmins, I.R.; Zaccardi, F.; Nelson, C.P.; Franks, P.W.; Yates, T.; Dudbridge, F. Genome-wide association study of self-reported walking pace suggests beneficial effects of brisk walking on health and survival. *Commun. Biol.* **2020**, *3*, 634. [[CrossRef](#)]
39. Ahmetov, I.; Kulemin, N.; Popov, D.; Naumov, V.; Akimov, E.; Bravy, Y.; Egorova, E.; Galeeva, A.; Generozov, E.; Kostryukova, E.; et al. Genome-wide association study identifies three novel genetic markers associated with elite endurance performance. *Biol. Sport* **2015**, *32*, 3–9. [[CrossRef](#)]

40. Rankinen, T.; Fuku, N.; Wolfarth, B.; Wang, G.; Sarzynski, M.A.; Alexeev, D.G.; Ahmetov, I.I.; Boulay, M.R.; Cieszczyk, P.; Eynon, N.; et al. No evidence of a common DNA variant profile specific to world class endurance athletes. *PLoS ONE* **2016**, *11*, e0147330. [[CrossRef](#)]
41. Pickering, C.; Suraci, B.; Semenova, E.A.; Boulygina, E.A.; Kostryukova, E.S.; Kulemin, N.A.; Borisov, O.V.; Khabibova, S.A.; Larin, A.K.; Pavlenko, A.V.; et al. A genome-wide association study of sprint performance in elite youth football players. *J. Strength Cond. Res.* **2019**, *33*, 2344–2351. [[CrossRef](#)]
42. Al-Khelaifi, F.; Yousri, N.A.; Diboun, I.; Semenova, E.A.; Kostryukova, E.S.; Kulemin, N.A.; Borisov, O.V.; Andryushchenko, L.B.; Larin, A.K.; Generozov, E.V.; et al. Genome-Wide Association Study Reveals a Novel Association Between MYBPC3 Gene Polymorphism, Endurance Athlete Status, Aerobic Capacity and Steroid Metabolism. *Front. Genet.* **2020**, *11*, 595. [[CrossRef](#)]
43. Semenova, E.A.; Zempo, H.; Miyamoto-Mikami, E.; Kumagai, H.; Larin, A.K.; Sultanov, R.I.; Babalyan, K.A.; Zhelankin, A.V.; Tobina, T.; Shiose, K.; et al. Genome-Wide Association Study Identifies CDKN1A as a Novel Locus Associated with Muscle Fiber Composition. *Cells* **2022**, *11*, 3910. [[CrossRef](#)]
44. Boulygina, E.A.; Borisov, O.V.; Valeeva, E.V.; Semenova, E.A.; Kostryukova, E.S.; Kulemin, N.A.; Larin, A.K.; Nabiullina, R.M.; Mavliev, F.A.; Akhatov, A.M.; et al. Whole genome sequencing of elite athletes. *Biol. Sport* **2020**, *37*, 295–304. [[CrossRef](#)]
45. Bulgay, C.; Kasakolu, A.; Kazan, H.H.; Mijaica, R.; Zorba, E.; Akman, O.; Bayraktar, I.; Ekmekci, R.; Koncagul, S.; Ulucan, K.; et al. Exome-Wide Association Study of Competitive Performance in Elite Athletes. *Genes* **2023**, *14*, 660. [[CrossRef](#)]
46. Malczewska-Lenczowska, J.; Orysiak, J.; Majorczyk, E.; Sitkowski, D.; Starczewski, M.; Zmijewski, P. HIF-1 α and NFIA-AS2 Polymorphisms as Potential Determinants of Total Hemoglobin Mass in Endurance Athletes. *J. Strength Cond. Res.* **2022**, *36*, 1596–1604. [[CrossRef](#)]
47. Díaz Ramírez, J.; Álvarez-Herms, J.; Castañeda-Babarro, A.; Larruskain, J.; Ramírez de la Piscina, X.; Borisov, O.V.; Semenova, E.A.; Kostryukova, E.S.; Kulemin, N.A.; Andryushchenko, O.N.; et al. The GALNTL6 Gene rs558129 Polymorphism is Associated with Power Performance. *J. Strength Cond. Res.* **2020**, *34*, 3031–3036. [[CrossRef](#)] [[PubMed](#)]
48. Guilherme, J.P.L.F.; Semenova, E.A.; Zempo, H.; Martins, G.L.; Lancha-Junior, A.H.; Miyamoto-Mikami, E.; Kumagai, H.; Tobina, T.; Shiose, K.; Kakigi, R.; et al. Are Genome-Wide Association Study Identified Single-Nucleotide Polymorphisms Associated with Sprint Athletic Status? A Replication Study With 3 Different Cohorts. *Int. J. Sport. Physiol. Perform.* **2021**, *16*, 489–495. [[CrossRef](#)] [[PubMed](#)]
49. Guilherme, J.P.L.F.; Semenova, E.A.; Larin, A.K.; Yusupov, R.A.; Generozov, E.V.; Ahmetov, I.I. Genomic Predictors of Brisk Walking Are Associated with Elite Sprinter Status. *Genes* **2022**, *13*, 1710. [[CrossRef](#)] [[PubMed](#)]
50. Guilherme, J.P.L.; Semenova, E.A.; Borisov, O.V.; Larin, A.K.; Moreland, E.; Generozov, E.V.; Ahmetov, I.I. Genomic predictors of testosterone levels are associated with muscle fiber size and strength. *Eur. J. Appl. Physiol.* **2022**, *122*, 415–423. [[CrossRef](#)] [[PubMed](#)]
51. Moreland, E.; Borisov, O.V.; Semenova, E.A.; Larin, A.K.; Andryushchenko, O.N.; Andryushchenko, L.B.; Generozov, E.V.; Williams, A.G.; Ahmetov, I.I. Polygenic Profile of Elite Strength Athletes. *J. Strength Cond. Res.* **2022**, *36*, 2509–2514. [[CrossRef](#)]
52. Ma, F.; Yang, Y.; Li, X.; Zhou, F.; Gao, C.; Li, M.; Gao, L. The association of sport performance with ACE and ACTN3 genetic polymorphisms: A systematic review and meta-analysis. *PLoS ONE* **2013**, *8*, e54685. [[CrossRef](#)]
53. Lopez-Leon, S.; Tuvblad, C.; Forero, D.A. Sports genetics: The PPARA gene and athletes' high ability in endurance sports. A systematic review and meta-analysis. *Biol. Sport* **2016**, *33*, 3–6. [[CrossRef](#)]
54. Chen, C.; Sun, Y.; Liang, H.; Yu, D.; Hu, S. A meta-analysis of the association of CKM gene rs8111989 polymorphism with sport performance. *Biol. Sport* **2017**, *34*, 323–330. [[CrossRef](#)]
55. Yvert, T.P.; Zempo, H.; Gabdrakhmanova, L.J.; Kikuchi, N.; Miyamoto-Mikami, E.; Murakami, H.; Naito, H.; Cieszczyk, P.; Leznicka, K.; Kostryukova, E.S.; et al. AGTR2 and sprint/power performance: A case-control replication study for rs11091046 polymorphism in two ethnicities. *Biol. Sport* **2018**, *35*, 105–109. [[CrossRef](#)]
56. Weyerstraß, J.; Stewart, K.; Wesselius, A.; Zeegers, M. Nine genetic polymorphisms associated with power athlete status—A Meta-Analysis. *J. Sci. Med. Sport* **2018**, *21*, 213–220. [[CrossRef](#)]
57. Chen, Y.; Wang, D.; Yan, P.; Yan, S.; Chang, Q.; Cheng, Z. Meta-analyses of the association between the PPARGC1A Gly482Ser polymorphism and athletic performance. *Biol. Sport* **2019**, *36*, 301–309. [[CrossRef](#)]
58. Tharabenjasin, P.; Pabalan, N.; Jarjanazi, H. Association of the ACTN3 R577X (rs1815739) polymorphism with elite power sports: A meta-analysis. *PLoS ONE* **2019**, *14*, e0217390. [[CrossRef](#)]
59. Tharabenjasin, P.; Pabalan, N.; Jarjanazi, H. Association of PPARGC1A Gly428Ser (rs8192678) polymorphism with potential for athletic ability and sports performance: A meta-analysis. *PLoS ONE* **2019**, *14*, e0200967. [[CrossRef](#)]
60. Guilherme, J.P.L.F.; Bosnyák, E.; Semenova, E.A.; Szmodis, M.; Griff, A.; Móra, Á.; Almási, G.; Trájer, E.; Udvardy, A.; Kostryukova, E.S.; et al. The MCT1 gene Glu490Asp polymorphism (rs1049434) is associated with endurance athlete status, lower blood lactate accumulation and higher maximum oxygen uptake. *Biol. Sport* **2021**, *38*, 465–474. [[CrossRef](#)]
61. McAuley, A.B.T.; Hughes, D.C.; Tsaprouni, L.G.; Varley, I.; Suraci, B.; Roos, T.R.; Herbert, A.J.; Kelly, A.L. The association of the ACTN3 R577X and ACE I/D polymorphisms with athlete status in football: A systematic review and meta-analysis. *J. Sport. Sci.* **2021**, *39*, 200–211. [[CrossRef](#)]
62. Ipekoglu, G.; Bulbul, A.; Cakir, H.I. A meta-analysis on the association of ACE and PPARA gene variants and endurance athletic status. *J. Sport. Med. Phys. Fitness* **2022**, *62*, 795–802. [[CrossRef](#)]

63. Konopka, M.J.; van den Bunder, J.C.M.L.; Rietjens, G.; Sperlich, B.; Zeegers, M.P. Genetics of long-distance runners and road cyclists—A systematic review with meta-analysis. *Scand. J. Med. Sci. Sport.* **2022**, *32*, 1414–1429. [[CrossRef](#)]
64. Saito, M.; Ginszt, M.; Semenova, E.A.; Massidda, M.; Huminska-Lisowska, K.; Michałowska-Sawczyn, M.; Homma, H.; Cięszczyk, P.; Okamoto, T.; Larin, A.K.; et al. Is COL1A1 Gene rs1107946 Polymorphism Associated with Sport Climbing Status and Flexibility? *Genes* **2022**, *13*, 403. [[CrossRef](#)]
65. Saito, M.; Ginszt, M.; Semenova, E.A.; Massidda, M.; Huminska-Lisowska, K.; Michałowska-Sawczyn, M.; Homma, H.; Cięszczyk, P.; Okamoto, T.; Larin, A.K.; et al. Genetic profile of sports climbing athletes from three different ethnicities. *Biol. Sport* **2022**, *39*, 913–919. [[CrossRef](#)]
66. Kikuchi, N.; Tajima, T.; Tamura, Y.; Yamanaka, Y.; Menuki, K.; Okamoto, T.; Sakamaki-Sunaga, M.; Sakai, A.; Hiranuma, K.; Nakazato, K. The ALDH2 rs671 polymorphism is associated with athletic status and muscle strength in a Japanese population. *Biol. Sport* **2022**, *39*, 429–434. [[CrossRef](#)]
67. De Almeida, K.Y.; Saito, M.; Homma, H.; Mochizuki, Y.; Saito, A.; Deguchi, M.; Kozuma, A.; Okamoto, T.; Nakazato, K.; Kikuchi, N. ALDH2 gene polymorphism is associated with fitness in the elderly Japanese population. *J. Physiol. Anthropol.* **2022**, *41*, 38. [[CrossRef](#)] [[PubMed](#)]
68. Saito, A.; Saito, M.; Almeida, K.Y.; Homma, H.; Deguchi, M.; Kozuma, A.; Kobatake, N.; Okamoto, T.; Nakazato, K.; Kikuchi, N. The Association between the ALDH2 rs671 Polymorphism and Athletic Performance in Japanese Power and Strength Athletes. *Genes* **2022**, *13*, 1735. [[CrossRef](#)] [[PubMed](#)]
69. Ahmetov, I.I.; Donnikov, A.E.; Trofimov, D.Y. Actn3 genotype is associated with testosterone levels of athletes. *Biol. Sport* **2014**, *31*, 105–108. [[CrossRef](#)] [[PubMed](#)]
70. Baranova, T.I.; Berlov, D.N.; Glotov, O.S.; Korf, E.A.; Minigalin, A.D.; Mitrofanova, A.V.; Ahmetov, I.I.; Glotov, A.S. Genetic determination of the vascular reactions in humans in response to the diving reflex. *Am. J. Physiol. Heart Circ. Physiol.* **2017**, *312*, H622–H631. [[CrossRef](#)] [[PubMed](#)]
71. Leońska-Duniec, A.; Ahmetov, I.I.; Zmijewski, P. Genetic variants influencing effectiveness of exercise training programmes in obesity—an overview of human studies. *Biol. Sport* **2016**, *33*, 207–214. [[CrossRef](#)]
72. Leońska-Duniec, A.; Jastrzębski, Z.; Jazdzewska, A.; Moska, W.; Lulińska-Kuklik, E.; Sawczuk, M.; Gubaydullina, S.I.; Shakirova, A.T.; Cięszczyk, P.; Maszczyk, A.; et al. Individual Responsiveness to Exercise-Induced Fat Loss and Improvement of Metabolic Profile in Young Women is Associated with Polymorphisms of Adrenergic Receptor Genes. *J. Sport. Sci. Med.* **2018**, *17*, 134–144.
73. Leonska-Duniec, A.; Cięszczyk, P.; Ahmetov, I.I. Genes and individual responsiveness to exercise-induced fat loss. In *Sports, Exercise, and Nutritional Genomics: Current Status and Future Directions*; Barh, D., Ahmetov, I., Eds.; Academic Press: Cambridge, MA, USA, 2019; pp. 231–247. [[CrossRef](#)]
74. Massidda, M.; Miyamoto, N.; Beckley, S.; Kikuchi, N.; Fuku, N. Genetics of flexibility. In *Sports, Exercise, and Nutritional Genomics: Current Status and Future Directions*; Barh, D., Ahmetov, I., Eds.; Academic Press: Cambridge, MA, USA, 2019; pp. 273–293. [[CrossRef](#)]
75. Replonska, B.; Safranow, K.; Adamczyk, J.; Boguszewski, D.; Szymański, K.; Soltyszewski, I.; Barczak, A.; Siewierski, M.; Ploski, R.; Sozanski, H.; et al. Association of serotonergic pathway gene variants with elite athletic status in the Polish population. *J. Sport. Sci.* **2019**, *37*, 1655–1662. [[CrossRef](#)]
76. Yusof, H.A.; Aziz, A.R.; Muhamed, A.M.C. The influence of angiotensin I-converting enzyme (ACE) I/D gene polymorphism on cardiovascular and muscular adaptations following 8 weeks of isometric handgrip training (IHG) in untrained normotensive males. *Biol. Sport* **2019**, *36*, 81–94. [[CrossRef](#)]
77. Mazur, I.I.; Drozdovska, S.; Andrieieva, O.; Vinnichuk, Y.; Polishchuk, A.; Dosenko, V.; Andreev, I.; Pickering, C.; Ahmetov, I.I. PPARGC1A gene polymorphism is associated with exercise-induced fat loss. *Mol. Biol. Rep.* **2020**, *47*, 7451–7457. [[CrossRef](#)]
78. Zhao, Y.; Huang, G.; Chen, Z.; Fan, X.; Huang, T.; Liu, J.; Zhang, Q.; Shen, J.; Li, Z.; Shi, Y. Four Loci Are Associated with Cardiorespiratory Fitness and Endurance Performance in Young Chinese Females. *Sci. Rep.* **2020**, *10*, 10117. [[CrossRef](#)]
79. Mountford, H.S.; Hill, A.; Barnett, A.L.; Newbury, D.F. Genome-Wide Association Study of Motor Coordination. *Front. Hum. Neurosci.* **2021**, *15*, 669902. [[CrossRef](#)]
80. Williams, C.J.; Li, Z.; Harvey, N.; Lea, R.A.; Gurd, B.J.; Bonafiglia, J.T.; Papadimitriou, I.; Jacques, M.; Croci, I.; Stensvold, D.; et al. Genome wide association study of response to interval and continuous exercise training: The Predict-HIIT study. *J. Biomed. Sci.* **2021**, *28*, 37. [[CrossRef](#)]
81. Klevjer, M.; Nordeidet, A.N.; Hansen, A.F.; Madssen, E.; Wisløff, U.; Brumpton, B.M.; Bye, A. Genome-Wide Association Study Identifies New Genetic Determinants of Cardiorespiratory Fitness: The Trøndelag Health Study. *Med. Sci. Sport. Exerc.* **2022**, *54*, 1534–1545. [[CrossRef](#)]
82. Bojarczuk, A.; Boulygina, E.A.; Dzitkowska-Zabielska, M.; Łubkowska, B.; Leońska-Duniec, A.; Egorova, E.S.; Semenova, E.A.; Andryushchenko, L.B.; Larin, A.K.; Generozov, E.V.; et al. Genome-Wide Association Study of Exercise-Induced Fat Loss Efficiency. *Genes* **2022**, *13*, 1975. [[CrossRef](#)]
83. McAuley, A.B.T.; Hughes, D.C.; Tsaprouni, L.G.; Varley, I.; Suraci, B.; Baker, J.; Herbert, A.J.; Kelly, A.L. Genetic associations with personality and mental toughness profiles of English academy football players: An exploratory study. *Psychol. Sport Exerc.* **2022**, *61*, 102209. [[CrossRef](#)]

84. McAuley, A.B.; Hughes, D.C.; Tsaprouni, L.G.; Varley, I.; Suraci, B.; Baker, J.; Herbert, A.J.; Kelly, A.L. Genetic associations with technical capabilities in English academy football players: A preliminary study. *J. Sport. Med. Phys. Fitness* **2023**, *63*, 230–240. [[CrossRef](#)]
85. Tartar, J.L.; Cabrera, D.; Knafo, S.; Thomas, J.D.; Antonio, J.; Peacock, C.A. The “Warrior” COMT Val/Met Genotype Occurs in Greater Frequencies in Mixed Martial Arts Fighters Relative to Controls. *J. Sport. Sci. Med.* **2020**, *19*, 38–42.
86. Ahmetov, I.I.; Valeeva, E.V.; Yerdenova, M.B.; Datkhabayeva, G.K.; Bouzid, A.; Bhamidimarri, P.M.; Sharafetdinova, L.M.; Egorova, E.S.; Semenova, E.A.; Gabdrakhmanova, L.J.; et al. KIBRA Gene Variant Is Associated with Ability in Chess and Science. *Genes* **2023**, *14*, 204. [[CrossRef](#)]
87. Womack, C.J.; Saunders, M.J.; Bechtel, M.K.; Bolton, D.J.; Martin, M.; Luden, N.D.; Dunham, W.; Hancock, M. The influence of a CYP1A2 polymorphism on the ergogenic effects of caffeine. *J. Int. Soc. Sport. Nutr.* **2012**, *9*, 7. [[CrossRef](#)]
88. Guest, N.S.; Horne, J.; Vanderhout, S.M.; El-Sohehy, A. Sport Nutrigenomics: Personalized Nutrition for Athletic Performance. *Front. Nutr.* **2019**, *6*, 8. [[CrossRef](#)]
89. Guest, N.; Corey, P.; Vescovi, J.; El-Sohehy, A. Caffeine, CYP1A2 Genotype, and Endurance Performance in Athletes. *Med. Sci. Sport. Exerc.* **2018**, *50*, 1570–1578. [[CrossRef](#)] [[PubMed](#)]
90. Guest, N.S.; Corey, P.; Tyrrell, P.N.; El-Sohehy, A. Effect of Caffeine on Endurance Performance in Athletes May Depend on HTR2A and CYP1A2 Genotypes. *J. Strength Cond. Res.* **2022**, *36*, 2486–2492. [[CrossRef](#)] [[PubMed](#)]
91. Muñoz, A.; López-Samanes, Á.; Aguilar-Navarro, M.; Varillas-Delgado, D.; Rivilla-García, J.; Moreno-Pérez, V.; Del Coso, J. Effects of CYP1A2 and ADORA2A Genotypes on the Ergogenic Response to Caffeine in Professional Handball Players. *Genes* **2020**, *11*, 933. [[CrossRef](#)] [[PubMed](#)]
92. Wong, O.; Marshall, K.; Sicova, M.; Guest, N.S.; García-Bailo, B.; El-Sohehy, A. CYP1A2 Genotype Modifies the Effects of Caffeine Compared With Placebo on Muscle Strength in Competitive Male Athletes. *Int. J. Sport Nutr. Exerc. Metab.* **2021**, *31*, 420–426. [[CrossRef](#)]
93. Sicova, M.; Guest, N.S.; Tyrrell, P.N.; El-Sohehy, A. Caffeine, genetic variation and anaerobic performance in male athletes: A randomized controlled trial. *Eur. J. Appl. Physiol.* **2021**, *121*, 3499–3513. [[CrossRef](#)]
94. Hall, E.C.R.; Semenova, E.A.; Bondareva, E.A.; Andryushchenko, L.B.; Larin, A.K.; Cieszczyk, P.; Generozov, E.V.; Ahmetov, I.I. Association of Genetically Predicted BCAA Levels with Muscle Fiber Size in Athletes Consuming Protein. *Genes* **2022**, *13*, 397. [[CrossRef](#)]
95. Rahimi, R. The effect of CYP1A2 genotype on the ergogenic properties of caffeine during resistance exercise: A randomized, double-blind, placebo-controlled, crossover study. *Ir. J. Med. Sci.* **2019**, *188*, 337–345. [[CrossRef](#)]
96. Loy, B.D.; O’Connor, P.J.; Lindheimer, J.B.; Covert, S.F. Caffeine is ergogenic for adenosine A2A receptor gene (ADORA2A) T allele homozygotes: A pilot study. *J. Caffeine Res.* **2015**, *5*, 73–81. [[CrossRef](#)]
97. Pickering, C.; Kiely, J. Are the current guidelines on caffeine use in sport optimal for everyone? Inter-individual variation in caffeine ergogenicity, and a move towards personalised sports nutrition. *Sport. Med.* **2018**, *48*, 7–16. [[CrossRef](#)]
98. Thomas, R.; Algrain, H.; Ryan, E.; Popojas, A.; Carrigan, P.; Abdulrahman, A.; Carrillo, A. Influence of a CYP1A2 polymorphism on post-exercise heart rate variability in response to caffeine intake: A double-blind, placebo-controlled trial. *Ir. J. Med. Sci.* **2017**, *186*, 285–291. [[CrossRef](#)]
99. Rahimi, M.R.; Semenova, E.A.; Larin, A.K.; Kulemin, N.A.; Generozov, E.V.; Łubkowska, B.; Ahmetov, I.I.; Golpasandi, H. The ADORA2A TT Genotype Is Associated with Anti-Inflammatory Effects of Caffeine in Response to Resistance Exercise and Habitual Coffee Intake. *Nutrients* **2023**, *15*, 1634. [[CrossRef](#)]
100. Guntoro, A.Y.; Melita, S.; Dijaya, R.; Subali, D.; Kartawidjajaputra, F.; Suwanto, A. Evaluation of Caffeine Ingested Timing on Endurance Performance based on CYP1A2 rs762551 Profiling in Healthy Sedentary Young Adults. *Rep. Biochem. Mol. Biol.* **2023**, *11*, 663–671. [[CrossRef](#)]
101. Rahim, M.; Collins, M.; September, A. Genes and Musculoskeletal Soft-Tissue Injuries. *Med. Sport Sci.* **2016**, *61*, 68–91. [[CrossRef](#)]
102. Kim, S.K.; Roche, M.D.; Fredericson, M.; Dragoo, J.L.; Horton, B.H.; Avins, A.L.; Belanger, H.G.; Ioannidis, J.P.A.; Abrams, G.D. A Genome-wide Association Study for Concussion Risk. *Med. Sci. Sport. Exerc.* **2021**, *53*, 704–711. [[CrossRef](#)]
103. Lim, T.; Santiago, C.; Pareja-Galeano, H.; Iturriaga, T.; Sosa-Pedreschi, A.; Fuku, N.; Pérez-Ruiz, M.; Yvert, T. Genetic variations associated with non-contact muscle injuries in sport: A systematic review. *Scand. J. Med. Sci. Sport.* **2021**, *31*, 2014–2032. [[CrossRef](#)]
104. Antrobus, M.R.; Brazier, J.; Stebbings, G.K.; Day, S.H.; Heffernan, S.M.; Kilduff, L.P.; Erskine, R.M.; Williams, A.G. Genetic Factors That Could Affect Concussion Risk in Elite Rugby. *Sports* **2021**, *9*, 19. [[CrossRef](#)]
105. Brazier, J.; Antrobus, M.R.; Herbert, A.J.; Callus, P.C.; Khanal, P.; Stebbings, G.K.; Day, S.H.; Heffernan, S.M.; Kilduff, L.P.; Bennett, M.A.; et al. Gene variants previously associated with reduced soft-tissue injury risk: Part 2—Polygenic associations with elite status in Rugby. *Eur. J. Sport Sci.* **2022**, *26*, 1–10. [[CrossRef](#)]
106. Brazier, J.; Antrobus, M.R.; Herbert, A.J.; Callus, P.C.; Stebbings, G.K.; Day, S.H.; Heffernan, S.M.; Kilduff, L.P.; Bennett, M.A.; Erskine, R.M.; et al. Gene variants previously associated with reduced soft tissue injury risk: Part 1—Independent associations with elite status in rugby. *Eur. J. Sport Sci.* **2022**, *29*, 1–10. [[CrossRef](#)]
107. de Almeida, K.Y.; Cetolin, T.; Marrero, A.R.; Aguiar Junior, A.S.; Mohr, P.; Kikuchi, N. A Pilot Study on the Prediction of Non-Contact Muscle Injuries Based on ACTN3 R577X and ACE I/D Polymorphisms in Professional Soccer Athletes. *Genes* **2022**, *13*, 2009. [[CrossRef](#)]

108. Ginevičienė, V.; Urnikytė, A. Association of COL12A1 rs970547 Polymorphism with Elite Athlete Status. *Biomedicines* **2022**, *10*, 2495. [[CrossRef](#)]
109. Jacob, Y.; Anderton, R.S.; Cochrane Wilkie, J.L.; Rogalski, B.; Laws, S.M.; Jones, A.; Spiteri, T.; Hince, D.; Hart, N.H. Genetic Variants within NOGGIN, COL1A1, COL5A1, and IGF2 are Associated with Musculoskeletal Injuries in Elite Male Australian Football League Players: A Preliminary Study. *Sport. Med. Open* **2022**, *8*, 126. [[CrossRef](#)] [[PubMed](#)]
110. Antrobus, M.R.; Brazier, J.; Callus, P.C.; Herbert, A.J.; Stebbings, G.K.; Khanal, P.; Day, S.H.; Kilduff, L.P.; Bennett, M.A.; Erskine, R.M.; et al. Concussion-Associated Polygenic Profiles of Elite Male Rugby Athletes. *Genes* **2022**, *13*, 820. [[CrossRef](#)]
111. Hall, E.C.R.; Baumert, P.; Larruskain, J.; Gil, S.M.; Lekue, J.A.; Rienzi, E.; Moreno, S.; Tannure, M.; Murtagh, C.F.; Ade, J.D.; et al. The genetic association with injury risk in male academy soccer players depends on maturity status. *Scand. J. Med. Sci. Sport.* **2022**, *32*, 338–350. [[CrossRef](#)] [[PubMed](#)]
112. Kumagai, H.; Miyamoto-Mikami, E.; Kikuchi, N.; Kamiya, N.; Zempo, H.; Fuku, N. A rs936306 C/T Polymorphism in the CYP19A1 Is Associated with Stress Fractures. *J. Strength Cond. Res.* **2022**, *36*, 2322–2325. [[CrossRef](#)] [[PubMed](#)]
113. Varillas-Delgado, D.; Morencos, E.; Gutierrez-Hellín, J.; Aguilar-Navarro, M.; Maestro, A.; Perucho, T.; Coso, J.D. Association of the CKM rs8111989 Polymorphism with Injury Epidemiology in Football Players. *Int. J. Sport. Med.* **2023**, *44*, 145–152. [[CrossRef](#)]
114. Varillas-Delgado, D.; Gutierrez-Hellín, J.; Maestro, A. Genetic Profile in Genes Associated with Sports Injuries in Elite Endurance Athletes. *Int. J. Sport. Med.* **2023**, *44*, 64–71. [[CrossRef](#)]
115. Ahmetov, I.I.; Hall, E.C.R.; Semenova, E.A.; Pranckevičienė, E.; Ginevičienė, V. Advances in sports genomics. *Adv. Clin. Chem.* **2022**, *107*, 215–263. [[CrossRef](#)]
116. Egorova, E.S.; Borisova, A.V.; Mustafina, L.J.; Arkhipova, A.A.; Gabbasov, R.T.; Druzhevskaya, A.M.; Astratenkova, I.V.; Ahmetov, I.I. The polygenic profile of Russian football players. *J. Sport. Sci.* **2014**, *32*, 1286–1293. [[CrossRef](#)]
117. Youn, B.Y.; Ko, S.G.; Kim, J.Y. Genetic basis of elite combat sports athletes: A systematic review. *Biol. Sport* **2021**, *38*, 667–675. [[CrossRef](#)]
118. Abernethy, P.J.; Thayer, R.; Taylor, A.W. Acute and chronic responses of skeletal muscle to endurance and sprint exercise. A review. *Sports Med.* **1990**, *10*, 365–389. [[CrossRef](#)]
119. Simoneau, J.A.; Bouchard, C. Genetic determinism of fiber type proportion in human skeletal muscle. *FASEB J.* **1995**, *9*, 1091–1095. [[CrossRef](#)]
120. Bassett, D.R., Jr.; Howley, E.T. Limiting factors for maximum oxygen uptake and determinants of endurance performance. *Med. Sci. Sport. Exerc.* **2000**, *32*, 70–84. [[CrossRef](#)]
121. Ahmetov, I.I.; Vinogradova, O.L.; Williams, A.G. Gene polymorphisms and fiber-type composition of human skeletal muscle. *Int. J. Sport Nutr. Exerc. Metab.* **2012**, *22*, 292–303. [[CrossRef](#)]
122. Malczewska-Lenczowska, J.; Orysiak, J.; Majorczyk, E.; Zdanowicz, R.; Szczepańska, B.; Starczewski, M.; Kaczmarski, J.; Dybek, T.; Pokrywka, A.; Ahmetov, I.I.; et al. Total Hemoglobin Mass, Aerobic Capacity, and HBB Gene in Polish Road Cyclists. *J. Strength Cond. Res.* **2016**, *30*, 3512–3519. [[CrossRef](#)]
123. Semenova, E.A.; Khabibova, S.A.; Borisov, O.V.; Generozov, E.V.; Ahmetov, I.I. The Variability of DNA Structure and Muscle-Fiber Composition. *Hum. Physiol.* **2019**, *45*, pp. 225–232. [[CrossRef](#)]
124. Konopka, M.J.; Zeegers, M.P.; Solberg, P.A.; Delhaije, L.; Meeusen, R.; Ruigrok, G.; Rietjens, G.; Sperlich, B. Factors associated with high-level endurance performance: An expert consensus derived via the Delphi technique. *PLoS ONE* **2022**, *17*, e0279492. [[CrossRef](#)]
125. Miyamoto-Mikami, E.; Zempo, H.; Fuku, N.; Kikuchi, N.; Miyachi, M.; Murakami, H. Heritability estimates of endurance-related phenotypes: A systematic review and meta-analysis. *Scand. J. Med. Sci. Sport.* **2018**, *28*, 834–845. [[CrossRef](#)]
126. Ahmetov, I.I.; Fedotovskaya, O.N. Current Progress in Sports Genomics. *Adv. Clin. Chem.* **2015**, *70*, 247–314. [[CrossRef](#)]
127. Ahmetov, I.I.; Egorova, E.S.; Gabdrakhmanova, L.J.; Fedotovskaya, O.N. Genes and Athletic Performance: An Update. *Med. Sport Sci.* **2016**, *61*, 41–54. [[CrossRef](#)]
128. Myerson, S.; Hemingway, H.; Budget, R.; Martin, J.; Humphries, S.; Montgomery, H. Human angiotensin I-converting enzyme gene and endurance performance. *J. Appl. Physiol.* **1999**, *87*, 1313–1316. [[CrossRef](#)]
129. Jelakovic, B.; Kuzmanic, D.; Milicic, D. Influence of angiotensin converting enzyme (ACE) gene polymorphism and circadian blood pressure (BP) changes on left ventricle (LV) mass in competitive oarsmen. *Am. J. Hypertens.* **2000**, *13*, 182A. [[CrossRef](#)]
130. Ahmetov, I.I.; Popov, D.V.; Astratenkova, I.V.; Druzhevskaya, A.M.; Missina, S.S.; Vinogradova, O.L.; Rogozkin, V.A. The use of molecular genetic methods for prognosis of aerobic and anaerobic performance in athletes. *Hum. Physiol.* **2008**, *34*, 338–342. [[CrossRef](#)]
131. Alvarez, R.; Terrados, N.; Ortolano, R.; Iglesias-Cubero, G.; Reguero, J.R.; Batalla, A.; Cortina, A.; Fernández-García, B.; Rodríguez, C.; Braga, S.; et al. Genetic variation in the renin-angiotensin system and athletic performance. *Eur. J. Appl. Physiol.* **2000**, *82*, 117–120. [[CrossRef](#)] [[PubMed](#)]
132. Collins, M.; Xenophontos, S.L.; Cariolou, M.A.; Mokone, G.G.; Hudson, D.E.; Anastasiades, L.; Noakes, T.D. The ACE gene and endurance performance during the South African Ironman Triathlons. *Med. Sci. Sport. Exerc.* **2004**, *36*, 1314–1320. [[CrossRef](#)] [[PubMed](#)]
133. Lucía, A.; Gómez-Gallego, F.; Chicharro, J.L.; Hoyos, J.; Celaya, K.; Córdova, A.; Villa, G.; Alonso, J.M.; Barriopedro, M.; Pérez, M.; et al. Is there an association between ACE and CKMM polymorphisms and cycling performance status during 3-week races? *Int. J. Sport. Med.* **2005**, *26*, 442–447. [[CrossRef](#)]

134. Hruskovicová, H.; Dzurenková, D.; Selingerová, M.; Bohus, B.; Timkanicová, B.; Kovács, L. The angiotensin converting enzyme I/D polymorphism in long distance runners. *J. Sports Med. Phys. Fitness* **2006**, *46*, 509–513.
135. Scanavini, D.; Bernardi, F.; Castoldi, E.; Conconi, F.; Mazzoni, G. Increased frequency of the homozygous II ACE genotype in Italian Olympic endurance athletes. *Eur. J. Hum. Genet.* **2002**, *10*, 576–577. [[CrossRef](#)]
136. Turgut, G.; Turgut, S.; Genc, O.; Atalay, A.; Atalay, E.O. The angiotensin converting enzyme I/D polymorphism in Turkish athletes and sedentary controls. *Acta Med.* **2004**, *47*, 133–136. [[CrossRef](#)]
137. Tsianos, G.; Sanders, J.; Dhamrait, S.; Humphries, S.; Grant, S.; Montgomery, H. The ACE gene insertion/deletion polymorphism and elite endurance swimming. *Eur. J. Appl. Physiol.* **2004**, *92*, 360–362. [[CrossRef](#)]
138. Cieszczyk, P.; Krupecki, K.; Maciejewska, A.; Sawczuk, M. The angiotensin converting enzyme gene I/D polymorphism in Polish rowers. *Int. J. Sport. Med.* **2009**, *30*, 624–627. [[CrossRef](#)]
139. Min, S.K.; Takahashi, K.; Ishigami, H.; Hiranuma, K.; Mizuno, M.; Ishii, T.; Kim, C.S.; Nakazato, K. Is there a gender difference between ACE gene and race distance? *Appl. Physiol. Nutr. Metab.* **2009**, *34*, 926–932. [[CrossRef](#)]
140. Shenoy, S.; Tandon, S.; Sandhu, J.; Bhanwer, A.S. Association of Angiotensin Converting Enzyme gene Polymorphism and Indian Army Triathletes Performance. *Asian J. Sport. Med.* **2010**, *1*, 143–150. [[CrossRef](#)]
141. Znazen, H.; Mejri, A.; Touhami, I.; Chtara, M.; Siala, H.; LE Gallais, D.; Ahmetov, I.I.; Messaoud, T.; Chamari, K.; Soussi, N. Genetic advantageous predisposition of angiotensin converting enzyme id polymorphism in Tunisian athletes. *J. Sport. Med. Phys. Fit.* **2016**, *56*, 724–730.
142. Ash, G.I.; Scott, R.A.; Deason, M.; Dawson, T.A.; Wolde, B.; Bekele, Z.; Teka, S.; Pitsiladis, Y.P. No association between ACE gene variation and endurance athlete status in Ethiopians. *Med. Sci. Sport. Exerc.* **2011**, *43*, 590–597. [[CrossRef](#)]
143. Tobina, T.; Michishita, R.; Yamasawa, F.; Zhang, B.; Sasaki, H.; Tanaka, H.; Saku, K.; Kiyonaga, A. Association between the angiotensin I-converting enzyme gene insertion/deletion polymorphism and endurance running speed in Japanese runners. *J. Physiol. Sci.* **2010**, *60*, 325–330. [[CrossRef](#)]
144. Ahmetov, I.I.; Williams, A.G.; Popov, D.V.; Lyubaeva, E.V.; Hakimullina, A.M.; Fedotovskaya, O.N.; Mozhayskaya, I.A.; Vinogradova, O.L.; Astratenkova, I.V.; Montgomery, H.E.; et al. The combined impact of metabolic gene polymorphisms on elite endurance athlete status and related phenotypes. *Hum. Genet.* **2009**, *126*, 751–761. [[CrossRef](#)]
145. Papadimitriou, I.D.; Papadopoulos, C.; Kouvatsi, A.; Triantaphyllidis, C. The ACE I/D polymorphism in elite Greek track and field athletes. *J. Sport. Med. Phys. Fit.* **2009**, *49*, 459–463.
146. Scott, R.A.; Moran, C.; Wilson, R.H.; Onywera, V.; Boit, M.K.; Goodwin, W.H.; Gohlke, P.; Payne, J.; Montgomery, H.; Pitsiladis, Y.P. No association between Angiotensin Converting Enzyme (ACE) gene variation and endurance athlete status in Kenyans. *Comp. Biochem. Physiol. A Mol. Integr. Physiol.* **2005**, *141*, 169–175. [[CrossRef](#)]
147. Rankinen, T.; Wolfarth, B.; Simoneau, J.A.; Maier-Lenz, D.; Rauramaa, R.; Rivera, M.A.; Boulay, M.R.; Chagnon, Y.C.; Pérusse, L.; Keul, J.; et al. No association between the angiotensin-converting enzyme ID polymorphism and elite endurance athlete status. *J. Appl. Physiol.* **2000**, *88*, 1571–1575. [[CrossRef](#)]
148. Taylor, R.R.; Mamotte, C.D.; Fallon, K.; van Bockxmeer, F.M. Elite athletes and the gene for angiotensin-converting enzyme. *J. Appl. Physiol.* **1999**, *87*, 1035–1037. [[CrossRef](#)]
149. Orysiak, J.; Zmijewski, P.; Klusiewicz, A.; Kaliszewski, P.; Malczewska-Lenczowska, J.; Gajewski, J.; Pokrywka, A. The association between ace gene variation and aerobic capacity in winter endurance disciplines. *Biol. Sport* **2013**, *30*, 249–253. [[CrossRef](#)] [[PubMed](#)]
150. Ginevičienė, V.; Pranculis, A.; Jakaitienė, A.; Milašius, K.; Kučinskas, V. Genetic variation of the human ACE and ACTN3 genes and their association with functional muscle properties in Lithuanian elite athletes. *Medicina* **2011**, *47*, 40. [[CrossRef](#)] [[PubMed](#)]
151. Muniesa, C.A.; González-Freire, M.; Santiago, C.; Lao, J.I.; Buxens, A.; Rubio, J.C.; Martín, M.A.; Arenas, J.; Gomez-Gallego, F.; Lucia, A. World-class performance in lightweight rowing: Is it genetically influenced? A comparison with cyclists, runners and non-athletes. *Br. J. Sport. Med.* **2010**, *44*, 898–901. [[CrossRef](#)] [[PubMed](#)]
152. Papadimitriou, I.D.; Lockey, S.J.; Voisin, S.; Herbert, A.J.; Garton, F.; Houweling, P.J.; Cieszczyk, P.; Maciejewska-Skrendo, A.; Sawczuk, M.; Massidda, M.; et al. No association between ACTN3 R577X and ACE I/D polymorphisms and endurance running times in 698 Caucasian athletes. *BMC Genomics* **2018**, *19*, 13. [[CrossRef](#)] [[PubMed](#)]
153. Varillas-Delgado, D.; Morencos, E.; Gutiérrez-Hellín, J.; Aguilar-Navarro, M.; Muñoz, A.; Mendoza Láiz, N.; Perucho, T.; Maestro, A.; Tellería-Orriols, J.J. Genetic profiles to identify talents in elite endurance athletes and professional football players. *PLoS ONE* **2022**, *17*, e0274880. [[CrossRef](#)]
154. Shang, X.; Huang, C.; Chang, Q.; Zhang, L.; Huang, T. Association between the ACTN3 R577X polymorphism and female endurance athletes in China. *Int. J. Sport. Med.* **2010**, *31*, 913–916. [[CrossRef](#)]
155. Gasser, B.; Flück, M.; Frey, W.O.; Valdivieso, P.; Spörri, J. Association of Gene Variants for Mechanical and Metabolic Muscle Quality with Cardiorespiratory and Muscular Variables Related to Performance in Skiing Athletes. *Genes* **2022**, *13*, 1798. [[CrossRef](#)]
156. Orysiak, J.; Sitkowski, D.; Zmijewski, P.; Malczewska-Lenczowska, J.; Cieszczyk, P.; Zembron-Lacny, A.; Pokrywka, A. Over-representation of the ACTN3 XX genotype in elite canoe and kayak paddlers. *J. Strength Cond. Res.* **2015**, *29*, 1107–1112. [[CrossRef](#)]
157. Ahmetov, I.I.; Druzhevskaya, A.M.; Astratenkova, I.V.; Popov, D.V.; Vinogradova, O.L.; Rogozkin, V.A. The ACTN3 R577X polymorphism in Russian endurance athletes. *Br. J. Sport. Med.* **2010**, *44*, 649–652. [[CrossRef](#)]

158. Döring, F.E.; Onur, S.; Geisen, U.; Boulay, M.R.; Pérusse, L.; Rankinen, T.; Rauramaa, R.; Wolfahrt, B.; Bouchard, C. ACTN3 R577X and other polymorphisms are not associated with elite endurance athlete status in the Genathlete study. *J. Sport. Sci.* **2010**, *28*, 1355–1359. [[CrossRef](#)]
159. Ginevičienė, V.; Prankevičienė, E.; Milašius, K.; Kučinskas, V. Relating fitness phenotypes to genotypes in Lithuanian elite athletes. *Acta Med. Litu.* **2010**, *17*, 1–10. [[CrossRef](#)]
160. Tsiianos, G.I.; Evangelou, E.; Boot, A.; Zillikens, M.C.; van Meurs, J.B.; Uitterlinden, A.G.; Ioannidis, J.P. Associations of polymorphisms of eight muscle- or metabolism-related genes with performance in Mount Olympus marathon runners. *J. Appl. Physiol.* **2010**, *108*, 567–574. [[CrossRef](#)]
161. Niemi, A.K.; Majamaa, K. Mitochondrial DNA and ACTN3 genotypes in Finnish elite endurance and sprint athletes. *Eur. J. Hum. Genet.* **2005**, *13*, 965–969. [[CrossRef](#)]
162. Papadimitriou, I.D.; Papadopoulou, C.; Kouvatsi, A.; Triantaphyllidis, C. The ACTN3 gene in elite Greek track and field athletes. *Int. J. Sport. Med.* **2008**, *29*, 352–355. [[CrossRef](#)]
163. Paparini, A.; Ripani, M.; Giordano, G.D.; Santoni, D.; Pigozzi, F.; Romano-Spica, V. ACTN3 genotyping by real-time PCR in the Italian population and athletes. *Med. Sci. Sport. Exerc.* **2007**, *39*, 810–815. [[CrossRef](#)]
164. Saunders, C.J.; September, A.V.; Xenophonos, S.L.; Cariolou, M.A.; Anastassiades, L.C.; Noakes, T.D.; Collins, M. No association of the ACTN3 gene R577X polymorphism with endurance performance in Ironman Triathlons. *Ann. Hum. Genet.* **2007**, *71*, 777–781. [[CrossRef](#)]
165. Yang, N.; MacArthur, D.G.; Wolde, B.; Onywere, V.O.; Boit, M.K.; Lau, S.Y.; Wilson, R.H.; Scott, R.A.; Pitsiladis, Y.P.; North, K. The ACTN3 R577X polymorphism in East and West African athletes. *Med. Sci. Sports Exerc.* **2007**, *39*, 1985–1988. [[CrossRef](#)]
166. Lucia, A.; Gómez-Gallego, F.; Santiago, C.; Bandrés, F.; Earnest, C.; Rabadán, M.; Alonso, J.M.; Hoyos, J.; Córdova, A.; Villa, G.; et al. ACTN3 genotype in professional endurance cyclists. *Int. J. Sports Med.* **2006**, *27*, 880–884. [[CrossRef](#)]
167. Grealy, R.; Smith, C.L.; Chen, T.; Hiller, D.; Haseler, L.J.; Griffiths, L.R. The genetics of endurance: Frequency of the ACTN3 R577X variant in Ironman World Championship athletes. *J. Sci. Med. Sport* **2013**, *16*, 365–371. [[CrossRef](#)]
168. Mikami, E.; Fuku, N.; Murakami, H.; Tsuchie, H.; Takahashi, H.; Ohiwa, N.; Tanaka, H.; Pitsiladis, Y.P.; Higuchi, M.; Miyachi, M.; et al. ACTN3 R577X genotype is associated with sprinting in elite Japanese athletes. *Int. J. Sport. Med.* **2014**, *35*, 172–177. [[CrossRef](#)]
169. Wang, G.; Mikami, E.; Chiu, L.L.; DE Perini, A.; Deason, M.; Fuku, N.; Miyachi, M.; Kaneoka, K.; Murakami, H.; Tanaka, M.; et al. Association analysis of ACE and ACTN3 in elite Caucasian and East Asian swimmers. *Med. Sci. Sport. Exerc.* **2013**, *45*, 892–900. [[CrossRef](#)] [[PubMed](#)]
170. Yang, R.; Jin, F.; Wang, L.; Shen, X.; Guo, Q.; Song, H.; Hu, J.; Zhao, Q.; Wan, J.; Cai, M. Prediction and Identification of Power Performance Using Polygenic Models of Three Single-Nucleotide Polymorphisms in Chinese Elite Athletes. *Front. Genet.* **2021**, *12*, 726552. [[CrossRef](#)] [[PubMed](#)]
171. Wagoner, L.E.; Craft, L.L.; Singh, B.; Suresh, D.P.; Zengel, P.W.; McGuire, N.; Abraham, W.T.; Chenier, T.C.; Dorn, G.W., 2nd; Liggett, S.B. Polymorphisms of the $\beta(2)$ -adrenergic receptor determine exercise capacity in patients with heart failure. *Circ. Res.* **2000**, *86*, 834–840. [[CrossRef](#)] [[PubMed](#)]
172. Wolfarth, B.; Rankinen, T.; Mühlbauer, S.; Scherr, J.; Boulay, M.R.; Pérusse, L.; Rauramaa, R.; Bouchard, C. Association between a beta2-adrenergic receptor polymorphism and elite endurance performance. *Metabolism* **2007**, *56*, 1649–1651. [[CrossRef](#)] [[PubMed](#)]
173. Santiago, C.; Ruiz, J.R.; Buxens, A.; Artieda, M.; Arteta, D.; González-Freire, M.; Rodríguez-Romo, G.; Altmäe, S.; Lao, J.I.; Gómez-Gallego, F.; et al. Trp64Arg polymorphism in ADRB3 gene is associated with elite endurance performance. *Br. J. Sport. Med.* **2011**, *45*, 147–149. [[CrossRef](#)]
174. Sawczuk, M.; Maciejewska-Karłowska, A.; Cieszczyk, P.; Skotarczak, B.; Ficek, K. Association of the ADRB2 Gly16Arg and Glu27Gln polymorphisms with athlete status. *J. Sports Sci.* **2013**, *31*, 1535–1544. [[CrossRef](#)]
175. Moore, G.E.; Shuldiner, A.R.; Zmuda, J.M.; Ferrell, R.E.; McCole, S.D.; Hagberg, J.M. Obesity gene variant and elite endurance performance. *Metabolism* **2001**, *50*, 1391–1392. [[CrossRef](#)]
176. Mustafina, L.J.; Naumov, V.A.; Cieszczyk, P.; Popov, D.V.; Lyubaeva, E.V.; Kostryukova, E.S.; Fedotovskaya, O.N.; Druzhevskaya, A.M.; Astratenkova, I.V.; Glotov, A.S.; et al. AGTR2 gene polymorphism is associated with muscle fibre composition, athletic status and aerobic performance. *Exp. Physiol.* **2014**, *99*, 1042–1052. [[CrossRef](#)]
177. Guilherme, J.P.L.F.; Silva, M.S.; Bertuzzi, R.; Lancha Junior, A.H. The AGTR2 rs11091046 (A>C) polymorphism and power athletic status in top-level Brazilian athletes. *J. Sport. Sci.* **2018**, *36*, 2327–2332. [[CrossRef](#)]
178. Martínez, J.L.; Carrión, A.; Florián, M.E.; Martín, J.A.; López-Taylor, J.R.; Fahey, T.D.; Rivera, M.A. Aquaporin-1 gene DNA variation predicts performance in Hispanic marathon runners. *Med. Sport* **2009**, *13*, 251–255. [[CrossRef](#)]
179. Rivera, M.A.; Martínez, J.L.; Carrion, A.; Fahey, T.D. AQP-1 association with body fluid loss in 10-km runners. *Int. J. Sport. Med.* **2011**, *32*, 229–233. [[CrossRef](#)]
180. Saunders, C.J.; Posthumus, M.; O’Connell, K.; September, A.V.; Collins, M. A variant within the AQP1 3’-untranslated region is associated with running performance, but not weight changes, during an Ironman Triathlon. *J. Sports Sci.* **2015**, *33*, 1342–1348. [[CrossRef](#)]
181. Rico-Sanz, J.; Rankinen, T.; Joannis, D.R.; Leon, A.S.; Skinner, J.S.; Wilmore, J.H.; Rao, D.C.; Bouchard, C.; HERITAGE Family study. Associations between cardiorespiratory responses to exercise and the C34T AMPD1 gene polymorphism in the HERITAGE Family Study. *Physiol. Genom.* **2003**, *14*, 161–166. [[CrossRef](#)]

182. Thomaes, T.; Thomis, M.; Onkelinx, S.; Fagard, R.; Matthijs, G.; Buys, R.; Schepers, D.; Cornelissen, V.; Vanhees, L. A genetic predisposition score for muscular endophenotypes predicts the increase in aerobic power after training: The CAREGENE study. *BMC Genet.* **2011**, *12*, 84. [[CrossRef](#)]
183. Ciężczyk, P.; Eider, J.; Ostanek, M.; Leońska-Duniec, A.; Ficek, K.; Kotarska, K.; Girdauskas, G. Is the C34T polymorphism of the AMPD1 gene associated with athlete performance in rowing? *Int. J. Sport. Med.* **2011**, *32*, 987–991. [[CrossRef](#)]
184. Ginevičienė, V.; Jakaitienė, A.; Pranculis, A.; Milašius, K.; Tubelis, L.; Utkus, A. AMPD1 rs17602729 is associated with physical performance of sprint and power in elite Lithuanian athletes. *BMC Genet.* **2014**, *15*, 58. [[CrossRef](#)]
185. Williams, A.G.; Dhamrait, S.S.; Wootton, P.T.; Day, S.H.; Hawe, E.; Payne, J.R.; Myerson, S.G.; World, M.; Budgett, R.; Humphries, S.E.; et al. Bradykinin receptor gene variant and human physical performance. *J. Appl. Physiol.* **2004**, *96*, 938–942. [[CrossRef](#)]
186. Saunders, C.J.; Xenophontos, S.L.; Cariolou, M.A.; Anastasiades, L.C.; Noakes, T.D.; Collins, M. The bradykinin β 2 receptor (BDKRB2) and endothelial nitric oxide synthase 3 (NOS3) genes and endurance performance during Ironman Triathlons. *Hum. Mol. Genet.* **2006**, *15*, 979–987. [[CrossRef](#)]
187. Sawczuk, M.; Timshina, Y.I.; Astratenkova, I.V.; Maciejewska-Karłowska, A.; Leońska-Duniec, A.; Ficek, K.; Mustafina, L.J.; Ciężczyk, P.; Klocek, T.; Ahmetov, I.I. The $-9/+9$ polymorphism of the bradykinin receptor β 2 gene and athlete status: A study involving two European cohorts. *Hum. Biol.* **2013**, *85*, 741–756. [[CrossRef](#)]
188. Grenda, A.; Leońska-Duniec, A.; Ciężczyk, P.; Zmijewski, P. Bdkrb2 gene $-9/+9$ polymorphism and swimming performance. *Biol. Sport* **2014**, *31*, 109–113. [[CrossRef](#)]
189. Zmijewski, P.; Grenda, A.; Leońska-Duniec, A.; Ahmetov, I.; Orysiak, J.; Ciężczyk, P. Effect of BDKRB2 Gene $-9/+9$ Polymorphism on Training Improvements in Competitive Swimmers. *J. Strength Cond. Res.* **2016**, *30*, 665–671. [[CrossRef](#)] [[PubMed](#)]
190. Rivera, M.A.; Dionne, F.T.; Simoneau, J.A.; Pérusse, L.; Chagnon, M.; Chagnon, Y.; Gagnon, J.; Leon, A.S.; Rao, D.C.; Skinner, J.S.; et al. Muscle-specific creatine kinase gene polymorphism and VO₂max in the HERITAGE Family Study. *Med. Sci. Sport. Exerc.* **1997**, *29*, 1311–1317. [[CrossRef](#)] [[PubMed](#)]
191. Rivera, M.A.; Pérusse, L.; Simoneau, J.A.; Gagnon, J.; Dionne, F.T.; Leon, A.S.; Skinner, J.S.; Wilmore, J.H.; Province, M.; Rao, D.C.; et al. Linkage between a muscle-specific CK gene marker and VO₂max in the HERITAGE Family Study. *Med. Sci. Sport. Exerc.* **1999**, *31*, 698–701. [[CrossRef](#)] [[PubMed](#)]
192. Fedotovskaya, O.N.; Popov, D.V.; Vinogradova, O.L.; Akhmetov, I.I. Association of muscle-specific creatine kinase (CKMM) gene polymorphism with physical performance of athletes. *Hum. Physiol.* **2012**, *38*, 89–93. [[CrossRef](#)]
193. Martínez, J.L.; Khorsandi, S.; Sojo, R.; Martínez, C.; Martín, J.A.; López-Taylor, J.R.; Fahey, T.D.; Rivera, M.A. Lack of an Association Between CKMM Genotype and Endurance Performance Level in Hispanic Marathon Runners. *Med. Sport* **2009**, *13*, 219–223. [[CrossRef](#)]
194. Posthumus, M.; Schweltnus, M.P.; Collins, M. The COL5A1 gene: A novel marker of endurance running performance. *Med. Sci. Sport. Exerc.* **2011**, *43*, 584–589. [[CrossRef](#)]
195. Brown, J.C.; Miller, C.J.; Posthumus, M.; Schweltnus, M.P.; Collins, M. The COL5A1 gene, ultra-marathon running performance, and range of motion. *Int. J. Sport. Physiol. Perform.* **2011**, *6*, 485–496. [[CrossRef](#)]
196. Guilherme, J.; Egorova, E.S.; Semenova, E.A.; Kostyryukova, E.S.; Kulemin, N.A.; Borisov, O.V.; Khabibova, S.A.; Larin, A.K.; Ospanova, E.A.; Pavlenko, A.V.; et al. The A-allele of the FTO gene rs9939609 polymorphism is associated with decreased proportion of slow oxidative muscle fibers and over-represented in heavier athletes. *J. Strength Cond. Res.* **2019**, *33*, 691–700. [[CrossRef](#)]
197. Zmijewski, P.; Leońska-Duniec, A. Association between the FTO A/T Polymorphism and Elite Athlete Status in Caucasian Swimmers. *Genes* **2021**, *12*, 715. [[CrossRef](#)]
198. Eynon, N.; Nasibulina, E.S.; Banting, L.K.; Cieszczyk, P.; Maciejewska-Karłowska, A.; Sawczuk, M.; Bondareva, E.A.; Shagimardanova, R.R.; Raz, M.; Sharon, Y.; et al. The FTO A/T polymorphism and elite athletic performance: A study involving three groups of European athletes. *PLoS ONE* **2013**, *8*, e60570. [[CrossRef](#)]
199. He, Z.; Hu, Y.; Feng, L.; Lu, Y.; Liu, G.; Xi, Y.; Wen, L.; McNaughton, L.R. NRF2 genotype improves endurance capacity in response to training. *Int. J. Sport. Med.* **2007**, *28*, 717–721. [[CrossRef](#)]
200. Eynon, N.; Ruiz, J.R.; Bishop, D.J.; Santiago, C.; Gómez-Gallego, F.; Lucia, A.; Birk, R. The rs12594956 polymorphism in the NRF-2 gene is associated with top-level Spanish athlete's performance status. *J. Sci. Med. Sport* **2013**, *16*, 135–139. [[CrossRef](#)]
201. Maciejewska-Karłowska, A.; Leońska-Duniec, A.; Ciężczyk, P.; Sawczuk, M.; Eider, J.; Ficek, K.; Sawczyn, S. The GABPB1 gene A/G polymorphism in Polish rowers. *J. Hum. Kinet.* **2012**, *31*, 115–120. [[CrossRef](#)]
202. Zarebska, A.; Jastrzebski, Z.; Kaczmarczyk, M.; Ficek, K.; Maciejewska-Karłowska, A.; Sawczuk, M.; Leońska-Duniec, A.; Krol, P.; Cieszczyk, P.; Zmijewski, P.; et al. The GSTP1 c.313A>G polymorphism modulates the cardiorespiratory response to aerobic training. *Biol. Sport* **2014**, *31*, 261–266. [[CrossRef](#)]
203. Zarebska, A.; Jastrzebski, Z.; Ahmetov, I.I.; Zmijewski, P.; Cieszczyk, P.; Leonska-Duniec, A.; Sawczuk, M.; Leznicka, K.; Trybek, G.; Semenova, E.A.; et al. GSTP1 c.313A>G polymorphism in Russian and Polish athletes. *Physiol. Genom.* **2017**, *49*, 127–131. [[CrossRef](#)]
204. Deugnier, Y.; Loréal, O.; Carré, F.; Duvallet, A.; Zoulim, F.; Vinel, J.P.; Paris, J.C.; Blaison, D.; Moirand, R.; Turlin, B.; et al. Increased body iron stores in elite road cyclists. *Med. Sci. Sport. Exerc.* **2002**, *34*, 876–880. [[CrossRef](#)]

205. Chicharro, J.L.; Hoyos, J.; Gómez-Gallego, F.; Villa, J.G.; Bandrés, F.; Celaya, P.; Jiménez, F.; Alonso, J.M.; Córdova, A.; Lucia, A. Mutations in the hereditary haemochromatosis gene HFE in professional endurance athletes. *Br. J. Sport. Med.* **2004**, *38*, 418–421. [[CrossRef](#)]
206. Hermine, O.; Dine, G.; Genty, V.; Marquet, L.A.; Fumagalli, G.; Tafflet, M.; Guillem, F.; Van Lierde, F.; Rousseaux-Blanchi, M.P.; Palierne, C.; et al. Eighty percent of French sport winners in Olympic, World and Europeans competitions have mutations in the hemochromatosis HFE gene. *Biochimie* **2015**, *119*, 1–5. [[CrossRef](#)]
207. Semenova, E.A.; Miyamoto-Mikami, E.; Akimov, E.B.; Al-Khelaifi, F.; Murakami, H.; Zempo, H.; Kostryukova, E.S.; Kulemin, N.A.; Larin, A.K.; Borisov, O.V.; et al. The association of HFE gene H63D polymorphism with endurance athlete status and aerobic capacity: Novel findings and a meta-analysis. *Eur. J. Appl. Physiol.* **2020**, *120*, 665–673. [[CrossRef](#)]
208. Prior, S.J.; Hagberg, J.M.; Phares, D.A.; Brown, M.D.; Fairfull, L.; Ferrell, R.E.; Roth, S.M. Sequence variation in hypoxia-inducible factor 1alpha (HIF1A): Association with maximal oxygen consumption. *Physiol. Genom.* **2003**, *15*, 20–26. [[CrossRef](#)]
209. Döring, F.; Onur, S.; Fischer, A.; Boulay, M.R.; Pérusse, L.; Rankinen, T.; Rauramaa, R.; Wolfarth, B.; Bouchard, C. A common haplotype and the Pro582Ser polymorphism of the hypoxia-inducible factor-1alpha (HIF1A) gene in elite endurance athletes. *J. Appl. Physiol.* **2010**, *108*, 1497–1500. [[CrossRef](#)] [[PubMed](#)]
210. Bosnyák, E.; Trájer, E.; Alszászi, G.; Móra, Á.; Györe, I.; Udvardy, A.; Tóth, M.; Szmodis, M. Lack of association between the GNB3 rs5443, HIF1A rs11549465 polymorphisms, physiological and functional characteristics. *Ann. Hum. Genet.* **2020**, *84*, 393–399. [[CrossRef](#)] [[PubMed](#)]
211. Merezhinskaya, N.; Fishbein, W.N.; Davis, J.I.; Foellmer, J.W. Mutations in MCT1 cDNA in patients with symptomatic deficiency in lactate transport. *Muscle Nerve* **2000**, *23*, 90–97. [[CrossRef](#)]
212. Cupeiro, R.; Benito, P.J.; Maffulli, N.; Calderón, F.J.; González-Lamuño, D. MCT1 genetic polymorphism influence in high intensity circuit training: A pilot study. *J. Sci. Med. Sport* **2010**, *13*, 526–530. [[CrossRef](#)]
213. Fedotovskaya, O.N.; Mustafina, L.J.; Popov, D.V.; Vinogradova, O.L.; Ahmetov, I.I. A common polymorphism of the MCT1 gene and athletic performance. *Int. J. Sport. Physiol. Perform.* **2014**, *9*, 173–180. [[CrossRef](#)]
214. Ramírez de la Piscina-Viúdez, X.; Álvarez-Herms, J.; Bonilla, D.A.; Castañeda-Babarro, A.; Larruskain, J.; Díaz-Ramírez, J.; Ahmetov, I.I.; Martínez-Ascensión, A.; Kreider, R.B.; Odriozola-Martínez, A. Putative Role of MCT1 rs1049434 Polymorphism in High-Intensity Endurance Performance: Concept and Basis to Understand Possible Individualization Stimulus. *Sports* **2021**, *9*, 143. [[CrossRef](#)]
215. Sawczuk, M.; Banting, L.K.; Cięszczyk, P.; Maciejewska-Karłowska, A.; Zarebska, A.; Leońska-Duniec, A.; Jastrzębski, Z.; Bishop, D.J.; Eynon, N. MCT1 A1470T: A novel polymorphism for sprint performance? *J. Sci. Med. Sport* **2015**, *18*, 114–118. [[CrossRef](#)]
216. Maruszak, A.; Adamczyk, J.G.; Siewierski, M.; Sozański, H.; Gajewski, A.; Żekanowski, C. Mitochondrial DNA variation is associated with elite athletic status in the Polish population. *Scand. J. Med. Sci. Sport.* **2014**, *24*, 311–318. [[CrossRef](#)]
217. Drozdovska, S.B.; Dosenko, V.E.; Ilyin, V.N.; Filippov, M.M.; Kuzmina, L.M. Allelic Polymorphism of Endothelial No-Synthase (eNOS) Association with Exercise-Induced Hypoxia Adaptation. *Baltic. J. Health Phys. Activ.* **2009**, *1*, 13–19. [[CrossRef](#)]
218. Zmijewski, P.; Cięszczyk, P.; Ahmetov, I.I.; Gronek, P.; Lulińska-Kuklik, E.; Dornowski, M.; Rzeszutko, A.; Chycki, J.; Moska, W.; Sawczuk, M. The NOS3 G894T (rs1799983) and -786T/C (rs2070744) polymorphisms are associated with elite swimmer status. *Biol. Sport* **2018**, *35*, 313–319. [[CrossRef](#)]
219. Gómez-Gallego, F.; Ruiz, J.R.; Buxens, A.; Artieda, M.; Arteta, D.; Santiago, C.; Rodríguez-Romo, G.; Lao, J.I.; Lucia, A. The -786 T/C polymorphism of the NOS3 gene is associated with elite performance in power sports. *Eur. J. Appl. Physiol.* **2009**, *107*, 565–569. [[CrossRef](#)]
220. Ahmetov, I.I.; Mozhayskaya, I.A.; Flavell, D.M.; Astratenkova, I.V.; Komkova, A.I.; Lyubaeva, E.V.; Tarakin, P.P.; Shenkman, B.S.; Vdovina, A.B.; Netreba, A.I.; et al. PPARalpha gene variation and physical performance in Russian athletes. *Eur. J. Appl. Physiol.* **2006**, *97*, 103–108. [[CrossRef](#)]
221. Maciejewska, A.; Sawczuk, M.; Cięszczyk, P. Variation in the PPAR α gene in Polish rowers. *J. Sci. Med. Sport* **2011**, *14*, 58–64. [[CrossRef](#)]
222. Tural, E.; Kara, N.; Agaoglu, S.A.; Elbistan, M.; Tasmektepligil, M.Y.; Imamoglu, O. PPAR- α and PPARGC1A gene variants have strong effects on aerobic performance of Turkish elite endurance athletes. *Mol. Biol. Rep.* **2014**, *41*, 5799–5804. [[CrossRef](#)]
223. Maciejewska, A.; Sawczuk, M.; Cięszczyk, P.; Mozhayskaya, I.A.; Ahmetov, I.I. The PPARGC1A gene Gly482Ser in Polish and Russian athletes. *J. Sport. Sci.* **2012**, *30*, 101–113. [[CrossRef](#)]
224. He, Z.H.; Hu, Y.; Li, Y.C.; Gong, L.J.; Cięszczyk, P.; Maciejewska-Karłowska, A.; Leonska-Duniec, A.; Muniesa, C.A.; Marin-Peiro, M.; Santiago, C.; et al. PGC-related gene variants and elite endurance athletic status in a Chinese cohort: A functional study. *Scand. J. Med. Sci. Sport.* **2015**, *25*, 184–195. [[CrossRef](#)]
225. Hall, E.C.R.; Lockey, S.J.; Heffernan, S.M.; Herbert, A.J.; Stebbings, G.K.; Day, S.H.; Collins, M.; Pitsiladis, Y.P.; Erskine, R.M.; Williams, A.G. The PPARGC1A Gly482Ser polymorphism is associated with elite long-distance running performance. *J. Sport. Sci.* **2023**, *41*, 56–62. [[CrossRef](#)]
226. Akhmetov, I.I.; Popov, D.V.; Missina, S.S.; Vinogradova, O.L.; Rogozkin, V.A. The analysis of PPARGC1B gene polymorphism in athletes. *Ross. Fiziol. Zh. Im. I.M. Sechenova* **2009**, *95*, 1247–1253.
227. Akhmetov, I.I.; Linde, E.V.; Shikhova, I.V.; Popov, D.V.; Missina, S.S.; Vinogradova, O.L.; Rogozkin, V.A. The influence of calcineurin gene polymorphism on morphofunctional characteristics of cardiovascular system of athletes. *Ross. Fiziol. Zh. Im. I.M. Sechenova* **2008**, *94*, 915–922.

228. Bouchard, C.; Sarzynski, M.A.; Rice, T.K.; Kraus, W.E.; Church, T.S.; Sung, Y.J.; Rao, D.C.; Rankinen, T. Genomic predictors of the maximal O₂ uptake response to standardized exercise training programs. *J. Appl. Physiol.* **2011**, *110*, 1160–1170. [[CrossRef](#)]
229. Hall, E.C.R.; Almeida, S.S.; Heffernan, S.M.; Lockey, S.J.; Herbert, A.J.; Callus, P.; Day, S.H.; Pedlar, C.R.; Kipps, C.; Collins, M.; et al. Genetic Polymorphisms Related to VO₂max Adaptation Are Associated with Elite Rugby Union Status and Competitive Marathon Performance. *Int. J. Sport. Physiol. Perform.* **2021**, *16*, 1858–1864. [[CrossRef](#)] [[PubMed](#)]
230. Kusić, D.; Connolly, J.; Kainulainen, H.; Semenova, E.A.; Borisov, O.V.; Larin, A.K.; Popov, D.V.; Generozov, E.V.; Ahmetov, I.I.; Britton, S.L.; et al. Striated muscle-specific serine/threonine-protein kinase β segregates with high versus low responsiveness to endurance exercise training. *Physiol. Genom.* **2020**, *52*, 35–46. [[CrossRef](#)] [[PubMed](#)]
231. Ahmetov, I.I.; Popov, D.V.; Missina, S.S.; Vinogradova, O.L.; Rogozkin, V.A. Association of mitochondrial transcription factor (TFAM) gene polymorphism with physical performance in athletes. *Hum. Physiol.* **2010**, *36*, 229–233. [[CrossRef](#)]
232. Gronek, P.; Gronek, J.; Lulińska-Kuklik, E.; Spieszny, M.; Niewczas, M.; Kaczmarczyk, M.; Petr, M.; Fischerova, P.; Ahmetov, I.I.; Zmijewski, P. Polygenic Study of Endurance-Associated Genetic Markers NOS3 (Glu298Asp), BDKRB2 (-9/+9), UCP2 (Ala55Val), AMPD1 (Gln45Ter) and ACE (I/D) in Polish Male Half Marathoners. *J. Hum. Kinet.* **2018**, *64*, 87–98. [[CrossRef](#)]
233. Hudson, D.E.; Mokone, G.G.; Noakes, T.D.; Collins, M. The -55 C/T polymorphism within the UCP3 gene and performance during the South African Ironman Triathlon. *Int. J. Sport. Med.* **2004**, *25*, 427–432. [[CrossRef](#)]
234. Prior, S.J.; Hagberg, J.M.; Paton, C.M.; Douglass, L.W.; Brown, M.D.; McLenithan, J.C.; Roth, S.M. DNA sequence variation in the promoter region of the VEGF gene impacts VEGF gene expression and maximal oxygen consumption. *Am. J. Physiol. Heart Circ. Physiol.* **2006**, *290*, H1848–H1855. [[CrossRef](#)]
235. Ahmetov, I.I.; Khakimullina, A.M.; Popov, D.V.; Missina, S.S.; Vinogradova, O.L.; Rogozkin, V.A. Polymorphism of the vascular endothelial growth factor gene (VEGF) and aerobic performance in athletes. *Hum. Physiol.* **2008**, *34*, 477–481. [[CrossRef](#)]
236. Ahmetov, I.I.; Hakimullina, A.M.; Popov, D.V.; Lyubaeva, E.V.; Missina, S.S.; Vinogradova, O.L.; Williams, A.G.; Rogozkin, V.A. Association of the VEGFR2 gene His472Gln polymorphism with endurance-related phenotypes. *Eur. J. Appl. Physiol.* **2009**, *107*, 95–103. [[CrossRef](#)]
237. Eider, J.; Leonska-Duniec, A.; Maciejewska-Karlowska, A.; Sawczuk, M.; Ficek, K.; Sawczyn, S. The VEGFR2 gene His472Gln polymorphism in Polish endurance athletes. *Int. SportMed. J.* **2013**, *14*, 29–35.
238. Kumagai, K.; Abe, T.; Brechue, W.F.; Ryushi, T.; Takano, S.; Mizuno, M. Sprint performance is related to muscle fascicle length in male 100-m sprinters. *J. Appl. Physiol.* **2000**, *88*, 811–816. [[CrossRef](#)]
239. Weyand, P.G.; Davis, J.A. Running performance has a structural basis. *J. Exp. Biol.* **2005**, *208*, 2625–2631. [[CrossRef](#)]
240. Uth, N. Anthropometric comparison of world-class sprinters and normal populations. *J. Sport. Sci. Med.* **2005**, *4*, 608–616.
241. Tønnessen, E.; Haugen, T.; Shalfawi, S.A. Reaction time aspects of elite sprinters in athletic world championships. *J. Strength Cond. Res.* **2013**, *27*, 885–892. [[CrossRef](#)]
242. Haugen, T.; Seiler, S.; Sandbakk, Ø.; Tønnessen, E. The Training and Development of Elite Sprint Performance: An Integration of Scientific and Best Practice Literature. *Sport. Med. Open* **2019**, *5*, 44. [[CrossRef](#)]
243. Suga, T.; Terada, M.; Tanaka, T.; Miyake, Y.; Ueno, H.; Otsuka, M.; Nagano, A.; Isaka, T. Calcaneus height is a key morphological factor of sprint performance in sprinters. *Sci. Rep.* **2020**, *10*, 15425. [[CrossRef](#)]
244. Hall, E.C.R.; Lysenko, E.A.; Semenova, E.A.; Borisov, O.V.; Andryushchenko, O.N.; Andryushchenko, L.B.; Vepkhvadze, T.F.; Lednev, E.M.; Zmijewski, P.; Popov, D.V.; et al. Prediction of muscle fiber composition using multiple repetition testing. *Biol. Sport* **2021**, *38*, 277–283. [[CrossRef](#)]
245. Hughes, D.C.; Day, S.H.; Ahmetov, I.I.; Williams, A.G. Genetics of muscle strength and power: Polygenic profile similarity limits skeletal muscle performance. *J. Sport. Sci.* **2011**, *29*, 1425–1434. [[CrossRef](#)]
246. Zempo, H.; Miyamoto-Mikami, E.; Kikuchi, N.; Fuku, N.; Miyachi, M.; Murakami, H. Heritability estimates of muscle strength-related phenotypes: A systematic review and meta-analysis. *Scand. J. Med. Sci. Sport.* **2017**, *27*, 1537–1546. [[CrossRef](#)]
247. Woods, D.; Hickman, M.; Jamshidi, Y.; Brull, D.; Vassiliou, V.; Jones, A.; Humphries, S.; Montgomery, H. Elite swimmers and the D allele of the ACE I/D polymorphism. *Hum. Genet.* **2001**, *108*, 230–232. [[CrossRef](#)]
248. Costa, A.M.; Silva, A.J.; Garrido, N.D.; Louro, H.; de Oliveira, R.J.; Breitenfeld, L. Association between ACE D allele and elite short distance swimming. *Eur. J. Appl. Physiol.* **2009**, *106*, 785–790. [[CrossRef](#)]
249. Boraita, A.; de la Rosa, A.; Heras, M.E.; de la Torre, A.I.; Canda, A.; Rabadán, M.; Díaz, A.E.; González, C.; López, M.; Hernández, M. Cardiovascular adaptation, functional capacity and Angiotensin-converting enzyme I/D polymorphism in elite athletes. *Rev. Esp. Cardiol.* **2010**, *63*, 810–819. [[CrossRef](#)] [[PubMed](#)]
250. Papadimitriou, I.D.; Lucia, A.; Pitsiladis, Y.P.; Pushkarev, V.P.; Dyatlov, D.A.; Orekhov, E.F.; Artioli, G.G.; Guilherme, J.P.; Lancha, A.H., Jr.; Ginevičienė, V.; et al. ACTN3 R577X and ACE I/D gene variants influence performance in elite sprinters: A multi-cohort study. *BMC Genom.* **2016**, *17*, 285. [[CrossRef](#)] [[PubMed](#)]
251. Amir, O.; Amir, R.; Yamin, C.; Attias, E.; Eynon, N.; Sagiv, M.; Sagiv, M.; Meckel, Y. The ACE deletion allele is associated with Israeli elite endurance athletes. *Exp. Physiol.* **2007**, *92*, 881–886. [[CrossRef](#)] [[PubMed](#)]
252. Kim, C.H.; Cho, J.Y.; Jeon, J.Y.; Koh, Y.G.; Kim, Y.M.; Kim, H.J.; Park, M.; Um, H.S.; Kim, C. ACE DD genotype is unfavorable to Korean short-term muscle power athletes. *Int. J. Sport. Med.* **2010**, *31*, 65–71. [[CrossRef](#)] [[PubMed](#)]
253. Shahmoradi, S.; Ahmadalipour, A.; Salehi, M. Evaluation of ACE gene I/D polymorphism in Iranian elite athletes. *Adv. Biomed. Res.* **2014**, *3*, 207. [[CrossRef](#)]

254. Scott, R.A.; Irving, R.; Irwin, L.; Morrison, E.; Charlton, V.; Austin, K.; Tladi, D.; Deason, M.; Headley, S.A.; Kolkhorst, F.W.; et al. ACTN3 and ACE genotypes in elite Jamaican and US sprinters. *Med. Sci. Sport. Exerc.* **2010**, *42*, 107–112. [[CrossRef](#)]
255. Windelinckx, A.; De Mars, G.; Huygens, W.; Peeters, M.W.; Vincent, B.; Wijmenga, C.; Lambrechts, D.; Delecluse, C.; Roth, S.M.; Metter, E.J.; et al. Comprehensive fine mapping of chr12q12-14 and follow-up replication identify activin receptor 1B (ACVR1B) as a muscle strength gene. *Eur. J. Hum. Genet.* **2011**, *19*, 208–215. [[CrossRef](#)]
256. Voisin, S.; Guilherme, J.P.; Yan, X.; Pushkarev, V.P.; Cieszczyk, P.; Massidda, M.; Calò, C.M.; Dyatlov, D.A.; Kolupaev, V.A.; Pushkareva, Y.E.; et al. ACVR1B rs2854464 Is Associated with Sprint/Power Athletic Status in a Large Cohort of Europeans but Not Brazilians. *PLoS ONE* **2016**, *11*, e0156316. [[CrossRef](#)]
257. Venckunas, T.; Degens, H. Genetic polymorphisms of muscular fitness in young healthy men. *PLoS ONE* **2022**, *17*, e0275179. [[CrossRef](#)]
258. Druzhevskaya, A.M.; Ahmetov, I.I.; Astratenkova, I.V.; Rogozkin, V.A. Association of the ACTN3 R577X polymorphism with power athlete status in Russians. *Eur. J. Appl. Physiol.* **2008**, *103*, 631–634. [[CrossRef](#)]
259. Massidda, M.; Vona, G.; Calò, C.M. Association between the ACTN3 R577X polymorphism and artistic gymnastic performance in Italy. *Genet. Test. Mol. Biomark.* **2009**, *13*, 377–380. [[CrossRef](#)]
260. Chiu, L.L.; Wu, Y.F.; Tang, M.T.; Yu, H.C.; Hsieh, L.L.; Hsieh, S.S. ACTN3 genotype and swimming performance in Taiwan. *Int. J. Sport. Med.* **2011**, *32*, 476–480. [[CrossRef](#)]
261. Ahmetov, I.I.; Druzhevskaya, A.M.; Lyubaeva, E.V.; Popov, D.V.; Vinogradova, O.L.; Williams, A.G. The dependence of preferred competitive racing distance on muscle fibre type composition and ACTN3 genotype in speed skaters. *Exp. Physiol.* **2011**, *96*, 1302–1310. [[CrossRef](#)]
262. Cieszczyk, P.; Eider, J.; Ostanek, M.; Arczewska, A.; Leońska-Duniec, A.; Sawczyn, S.; Ficek, K.; Krupecki, K. Association of the ACTN3 R577X Polymorphism in Polish Power-Orientated Athletes. *J. Hum. Kinet.* **2011**, *28*, 55–61. [[CrossRef](#)]
263. Yang, R.; Shen, X.; Wang, Y.; Voisin, S.; Cai, G.; Fu, Y.; Xu, W.; Eynon, N.; Bishop, D.J.; Yan, X. ACTN3 R577X Gene Variant Is Associated With Muscle-Related Phenotypes in Elite Chinese Sprint/Power Athletes. *J. Strength Cond. Res.* **2017**, *31*, 1107–1115. [[CrossRef](#)]
264. Akazawa, N.; Ohiwa, N.; Shimizu, K.; Suzuki, N.; Kumagai, H.; Fuku, N.; Suzuki, Y. The association of ACTN3 R577X polymorphism with sports specificity in Japanese elite athletes. *Biol. Sport* **2022**, *39*, 905–911. [[CrossRef](#)]
265. Koku, F.E.; Karamızrak, S.O.; Çiftçi, A.S.; Taşlıdere, H.; Durmaz, B.; Çoğulu, Ö. The relationship between ACTN3 R577X gene polymorphism and physical performance in amateur soccer players and sedentary individuals. *Biol. Sport* **2019**, *36*, 9–16. [[CrossRef](#)]
266. Zaccagni, L.; Lunghi, B.; Barbieri, D.; Rinaldo, N.; Missoni, S.; Šaric, T.; Šarac, J.; Babic, V.; Rakovac, M.; Bernardi, F.; et al. Performance prediction models based on anthropometric, genetic and psychological traits of Croatian sprinters. *Biol. Sport* **2019**, *36*, 17–23. [[CrossRef](#)]
267. Gomez-Gallego, F.; Santiago, C.; González-Freire, M.; Yvert, T.; Muniesa, C.A.; Serratos, L.; Altmäe, S.; Ruiz, J.R.; Lucia, A. The C allele of the AGT Met235Thr polymorphism is associated with power sports performance. *Appl. Physiol. Nutr. Metab.* **2009**, *34*, 1108–1111. [[CrossRef](#)]
268. Zarebska, A.; Sawczyn, S.; Kaczmarczyk, M.; Ficek, K.; Maciejewska-Karłowska, A.; Sawczuk, M.; Leońska-Duniec, A.; Eider, J.; Grenda, A.; Cieszczyk, P. Association of rs699 (M235T) polymorphism in the AGT gene with power but not endurance athlete status. *J. Strength Cond. Res.* **2013**, *27*, 2898–2903. [[CrossRef](#)]
269. Cieszczyk, P.; Ostanek, M.; Leońska-Duniec, A.; Sawczuk, M.; Maciejewska, A.; Eider, J.; Ficek, K.; Sygit, K.; Kotarska, K. Distribution of the AMPD1 C34T polymorphism in Polish power-oriented athletes. *J. Sport. Sci.* **2012**, *30*, 31–35. [[CrossRef](#)] [[PubMed](#)]
270. Fedotovskaya, O.N.; Danilova, A.A.; Akhmetov, I.I. Effect of AMPD1 gene polymorphism on muscle activity in humans. *Bull. Exp. Biol. Med.* **2013**, *154*, 489–491. [[CrossRef](#)] [[PubMed](#)]
271. Guilherme, J.P.L.F.; Semenova, E.A.; Borisov, O.V.; Kostyukova, E.S.; Vepkhvadze, T.F.; Lysenko, E.A.; Andryushchenko, O.N.; Andryushchenko, L.B.; Lednev, E.M.; Larin, A.K.; et al. The BDNF-Increasing Allele is Associated with Increased Proportion of Fast-Twitch Muscle Fibers, Handgrip Strength, and Power Athlete Status. *J. Strength Cond. Res.* **2022**, *36*, 1884–1889. [[CrossRef](#)] [[PubMed](#)]
272. Fedotovskaya, O.; Eider, J.; Cieszczyk, P.; Ahmetov, I.; Moska, W.; Sawczyn, S.; Leońska-Duniec, A.; Maciejewska-Karłowska, A.; Sawczuk, M.; Czubek, Z.; et al. Association of muscle-specific creatine kinase (CKM) gene polymorphism with combat athlete status in Polish and Russian cohorts. *Arch. Budo.* **2013**, *9*, 233–237.
273. He, E.P.; Li, Y.H.; Qian, J.D.; Yan, H.W. Association of CKMM gene A/G polymorphism and athletic performance of uighurnationality. *Zhongguo Ying Yong Sheng Li Xue Za Zhi* **2016**, *32*, 82–86.
274. Ginevičienė, V.; Jakaitienė, A.; Utkus, A.; Hall, E.C.R.; Semenova, E.A.; Andryushchenko, L.B.; Larin, A.K.; Moreland, E.; Generozov, E.V.; Ahmetov, I.I. CKM Gene rs8111989 Polymorphism and Power Athlete Status. *Genes* **2021**, *12*, 1499. [[CrossRef](#)]
275. Miyamoto-Mikami, E.; Fujita, Y.; Murakami, H.; Ito, M.; Miyachi, M.; Kawahara, T.; Fuku, N. CNTFR Genotype and Sprint/power Performance: Case-control Association and Functional Studies. *Int. J. Sport. Med.* **2016**, *37*, 411–417. [[CrossRef](#)]
276. Zmijewski, P.; Trybek, G.; Czarny, W.; Leońska-Duniec, A. GALNTL6 Rs558129: A Novel Polymorphism for Swimming Performance? *J. Hum. Kinet.* **2021**, *80*, 199–205. [[CrossRef](#)]

277. Cieszczyk, P.; Eider, J.; Arczewska, A.; Ostanek, M.; Leońska-Duniec, A.; Sawczyn, S.; Ficek, K.; Jascaniene, N.; Kotarska, K.; Sygit, K. The HIF1A gene Pro582Ser polymorphism in polish power-orientated athletes. *Biol. Sport* **2011**, *28*, 111–114. [[CrossRef](#)]
278. Gabbasov, R.T.; Arkhipova, A.A.; Borisova, A.V.; Hakimullina, A.M.; Kuznetsova, A.V.; Williams, A.G.; Day, S.H.; Ahmetov, I.I. The HIF1A Gene Pro582Ser Polymorphism in Russian Strength Athletes. *J. Strength Cond. Res.* **2013**, *27*, 2055–2058. [[CrossRef](#)]
279. Drozdovska, S.B.; Dosenko, V.E.; Ahmetov, I.I.; Ilyin, V.N. The association of gene polymorphisms with athlete status in ukrainians. *Biol. Sport* **2013**, *30*, 163–167. [[CrossRef](#)]
280. Ben-Zaken, S.; Meckel, Y.; Nemet, D.; Eliakim, A. Can IGF-I polymorphism affect power and endurance athletic performance? *Growth Horm. IGF Res.* **2013**, *23*, 175–178. [[CrossRef](#)]
281. Ben-Zaken, S.; Meckel, Y.; Rimmel, L.; Nemet, D.; Jürimäe, J.; Eliakim, A. The prevalence of IGF-I axis genetic polymorphisms among decathlon athletes. *Growth Horm. IGF Res.* **2022**, *64*, 101468. [[CrossRef](#)]
282. Itaka, T.; Agemizu, K.; Aruga, S.; Machida, S. G Allele of the IGF2 Apal Polymorphism Is Associated with Judo Status. *J. Strength Cond. Res.* **2016**, *30*, 2043–2048. [[CrossRef](#)]
283. Ruiz, J.R.; Buxens, A.; Artieda, M.; Arteta, D.; Santiago, C.; Rodríguez-Romo, G.; Lao, J.I.; Gómez-Gallego, F.; Lucia, A. The -174 G/C polymorphism of the IL6 gene is associated with elite power performance. *J. Sci. Med. Sport* **2010**, *13*, 549–553. [[CrossRef](#)]
284. Eider, J.; Cieszczyk, P.; Leońska-Duniec, A.; Maciejewska, A.; Sawczuk, M.; Ficek, K.; Kotarska, K. Association of the 174 G/C polymorphism of the IL6 gene in Polish power-orientated athletes. *J. Sport. Med. Phys. Fitness* **2013**, *53*, 88–92.
285. Terruzzi, I.; Senesi, P.; Montesano, A.; La Torre, A.; Alberti, G.; Benedini, S.; Caumo, A.; Fermo, I.; Luzi, L. Genetic polymorphisms of the enzymes involved in DNA methylation and synthesis in elite athletes. *Physiol. Genom.* **2011**, *43*, 965–973. [[CrossRef](#)]
286. Zarebska, A.; Ahmetov, I.; Sawczyn, S.; Weiner, A.S.; Kaczmarczyk, M.; Ficek, K.; Maciejewska-Karłowska, A.; Sawczuk, M.; Leonska-Duniec, A.; Klocek, T.; et al. Association of the MTHFR 1298A>C (rs1801131) polymorphism with speed and strength sports in Russian and Polish athletes. *J. Sport. Sci.* **2013**, *32*, 375–382. [[CrossRef](#)]
287. Murtagh, C.F.; Brownlee, T.E.; Rienzi, E.; Roquero, S.; Moreno, S.; Huertas, G.; Lugioratto, G.; Baumert, P.; Turner, D.C.; Lee, D.; et al. The genetic profile of elite youth soccer players and its association with power and speed depends on maturity status. *PLoS ONE* **2020**, *15*, e0234458. [[CrossRef](#)]
288. Nakamichi, R.; Ma, S.; Nonoyama, T.; Chiba, T.; Kurimoto, R.; Ohzono, H.; Olmer, M.; Shukunami, C.; Fuku, N.; Wang, G.; et al. The mechanosensitive ion channel PIEZO1 is expressed in tendons and regulates physical performance. *Sci. Transl. Med.* **2022**, *14*, eabj5557. [[CrossRef](#)]
289. Maciejewska-Skrendo, A.; Mieszkowski, J.; Kochanowicz, A.; Niespodziński, B.; Cieszczyk, P.; Leźnicka, K.; Leońska-Duniec, A.; Kolbowicz, M.; Kaczmarczyk, M.; Piskorska, E.; et al. Does the PPARA Intron 7 Gene Variant (rs4253778) Influence Performance in Power/Strength-Oriented Athletes? A Case-Control Replication Study in Three Cohorts of European Gymnasts. *J. Hum. Kinet.* **2021**, *79*, 77–85. [[CrossRef](#)] [[PubMed](#)]
290. Ahmetov, I.I.; Mozhayskaya, I.A.; Lyubaeva, E.V.; Vinogradova, O.L.; Rogozkin, V.A. PPARG Gene polymorphism and locomotor activity in humans. *Bull. Exp. Biol. Med.* **2008**, *146*, 630–632. [[CrossRef](#)] [[PubMed](#)]
291. Maciejewska-Karłowska, A.; Sawczuk, M.; Cieszczyk, P.; Zarebska, A.; Sawczyn, S. Association between the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ gene and strength athlete status. *PLoS ONE* **2013**, *8*, e67172. [[CrossRef](#)] [[PubMed](#)]
292. Guilherme, J.P.L.F.; Bertuzzi, R.; Lima-Silva, A.E.; Pereira, A.D.C.; Lancha Junior, A.H. Analysis of sports-relevant polymorphisms in a large Brazilian cohort of top-level athletes. *Ann. Hum. Genet.* **2018**, *82*, 254–264. [[CrossRef](#)]
293. Ahmetov, I.I.; Naumov, V.A.; Donnikov, A.E.; Maciejewska-Karłowska, A.; Kostryukova, E.S.; Larin, A.K.; Maykova, E.V.; Alexeev, D.G.; Fedotovskaya, O.N.; Generozov, E.V.; et al. SOD2 gene polymorphism and muscle damage markers in elite athletes. *Free Radic. Res.* **2014**, *48*, 948–955. [[CrossRef](#)]
294. Miyamoto-Mikami, E.; Murakami, H.; Tsuchie, H.; Takahashi, H.; Ohiwa, N.; Miyachi, M.; Kawahara, T.; Fuku, N. Lack of association between genotype score and sprint/power performance in the Japanese population. *J. Sci. Med. Sport* **2017**, *20*, 98–103. [[CrossRef](#)]
295. Khanal, P.; He, L.; Herbert, A.J.; Stebbings, G.K.; Onambele-Pearson, G.L.; Degens, H.; Morse, C.I.; Thomis, M.; Williams, A.G. The Association of Multiple Gene Variants with Ageing Skeletal Muscle Phenotypes in Elderly Women. *Genes* **2020**, *11*, 1459. [[CrossRef](#)]
296. Seaborne, R.A.; Hughes, D.C.; Turner, D.C.; Owens, D.J.; Baehr, L.M.; Gorski, P.; Semenova, E.A.; Borisov, O.V.; Larin, A.K.; Popov, D.V.; et al. UBR5 is a novel E3 ubiquitin ligase involved in skeletal muscle hypertrophy and recovery from atrophy. *J. Physiol.* **2019**, *597*, 3727–3749. [[CrossRef](#)]
297. Kuschel, L.B.; Sonnenburg, D.; Engel, T. Factors of Muscle Quality and Determinants of Muscle Strength: A Systematic Literature Review. *Healthcare* **2022**, *10*, 1937. [[CrossRef](#)]
298. Kikuchi, N.; Moreland, E.; Homma, H.; Semenova, E.A.; Saito, M.; Larin, A.K.; Kobatake, N.; Yusupov, R.A.; Okamoto, T.; Nakazato, K.; et al. Genes and Weightlifting Performance. *Genes* **2022**, *13*, 25. [[CrossRef](#)]
299. Colakoglu, M.; Cam, F.S.; Kayitken, B.; Cetinoz, F.; Colakoglu, S.; Turkmen, M.; Sayin, M. ACE genotype may have an effect on single versus multiple set preferences in strength training. *Eur. J. Appl. Physiol.* **2005**, *95*, 20–26. [[CrossRef](#)]
300. Giaccaglia, V.; Nicklas, B.; Kritchevsky, S.; Mychalecky, J.; Messier, S.; Bleecker, E.; Pahor, M. Interaction between angiotensin converting enzyme insertion/deletion genotype and exercise training on knee extensor strength in older individuals. *Int. J. Sport. Med.* **2008**, *29*, 40–44. [[CrossRef](#)]

301. Costa, A.M.; Silva, A.J.; Garrido, N.; Louro, H.; Marinho, D.A.; Cardoso Marques, M.; Breitenfeld, L. Angiotensin-converting enzyme genotype affects skeletal muscle strength in elite athletes. *J. Sport. Sci. Med.* **2009**, *8*, 410–418.
302. Pimjan, L.; Ongvarrasopone, C.; Chantratita, W.; Polpramool, C.; Cherdungsi, P.; Bangrak, P.; Yimlamai, T. A Study on ACE, ACTN3, and VDR Genes Polymorphism in Thai Weightlifters. *Walailak J. Sci. Technol. (WJST)* **2017**, *15*, 609–626. [[CrossRef](#)]
303. Melián Ortiz, A.; Laguarda-Val, S.; Varillas-Delgado, D. Muscle Work and Its Relationship with ACE and ACTN3 Polymorphisms Are Associated with the Improvement of Explosive Strength. *Genes* **2021**, *12*, 1177. [[CrossRef](#)]
304. Khanal, P.; Morse, C.I.; He, L.; Herbert, A.J.; Onambélé-Pearson, G.L.; Degens, H.; Thomis, M.; Williams, A.G.; Stebbings, G.K. Polygenic Models Partially Predict Muscle Size and Strength but Not Low Muscle Mass in Older Women. *Genes* **2022**, *13*, 982. [[CrossRef](#)]
305. Ginevičienė, V.; Jakaitienė, A.; Aksenov, M.O.; Aksenova, A.V.; Astratenkova, A.D.; Egorova, E.S.; Gabdrakhmanova, L.J.; Tubelis, L.; Kucinskas, V.; Utkus, A. Association analysis of ACE, ACTN3 and PPARC1A gene polymorphisms in two cohorts of European strength and power athletes. *Biol. Sport* **2016**, *33*, 199. [[CrossRef](#)]
306. Roth, S.M.; Walsh, S.; Liu, D.; Metter, E.J.; Ferrucci, L.; Hurley, B.F. The ACTN3 R577X nonsense allele is under-represented in elite-level strength athletes. *Eur. J. Hum. Genet.* **2007**, *16*, 391–394. [[CrossRef](#)]
307. Erskine, R.M.; Williams, A.G.; Jones, D.A.; Stewart, C.E.; Degens, H. The individual and combined influence of ACE and ACTN3 genotypes on muscle phenotypes before and after strength training. *Scand. J. Med. Sci Sport.* **2014**, *24*, 642–648. [[CrossRef](#)]
308. Homma, H.; Saito, M.; Saito, A.; Kozuma, A.; Matsumoto, R.; Matsumoto, S.; Kobatake, N.; Okamoto, T.; Nakazato, K.; Nishiyama, T.; et al. The Association between Total Genotype Score and Athletic Performance in Weightlifters. *Genes* **2022**, *13*, 2091. [[CrossRef](#)]
309. Orysiak, J.; Mazur-Różycka, J.; Busko, K.; Gajewski, J.; Szczepanska, B.; Malczewska-Lenczowska, J. Individual and Combined Influence of ACE and ACTN3 Genes on Muscle Phenotypes in Polish Athletes. *J. Strength Cond. Res.* **2018**, *32*, 2776–2782. [[CrossRef](#)] [[PubMed](#)]
310. Ben-Zaken, S.; Eliakim, A.; Nemet, D.; Meckel, Y. Genetic Variability among Power Athletes: The Stronger vs. Faster. *J. Strength Cond. Res.* **2019**, *33*, 1505–1511. [[CrossRef](#)] [[PubMed](#)]
311. Aleksandra, Z.; Zbigniew, J.; Waldemar, M.; Agata, L.D.; Mariusz, K.; Marek, S.; Agnieszka, M.S.; Piotr, Ż.; Krzysztof, F.; Grzegorz, T.; et al. The AGT Gene M235T Polymorphism and Response of Power-Related Variables to Aerobic Training. *J. Sport. Sci. Med.* **2016**, *15*, 616–624. [[PubMed](#)]
312. Matteini, A.M.; Tanaka, T.; Karasik, D.; Atzmon, G.; Chou, W.C.; Eicher, J.D.; Johnson, A.D.; Arnold, A.M.; Callisaya, M.L.; Davies, G.; et al. GWAS analysis of handgrip and lower body strength in older adults in the CHARGE consortium. *Aging Cell* **2016**, *15*, 792–800. [[CrossRef](#)] [[PubMed](#)]
313. Walsh, S.; Zmuda, J.M.; Cauley, J.A.; Shea, P.R.; Metter, E.J.; Hurley, B.F.; Ferrell, R.E.; Roth, S.M. Androgen receptor CAG repeat polymorphism is associated with fat-free mass in men. *J. Appl. Physiol.* **2005**, *98*, 132–137. [[CrossRef](#)]
314. Guilherme, J.P.L.; Shikhova, Y.V.; Dondukovskaya, R.R.; Topanova, A.A.; Semenova, E.A.; Astratenkova, I.V.; Ahmetov, I.I. Androgen receptor gene microsatellite polymorphism is associated with muscle mass and strength in bodybuilders and power athlete status. *Ann. Hum. Biol.* **2021**, *48*, 142–149. [[CrossRef](#)]
315. Fedotovskaia, O.N.; Popov, D.V.; Vinogradova, O.L.; Akhmetov, I.I. Association of the muscle-specific creatine kinase (CKMM) gene polymorphism with physical performance of athletes. *Fiziol. Cheloveka* **2012**, *38*, 105–109. [[CrossRef](#)]
316. Homma, H.; Kobatake, N.; Sekimoto, Y.; Saito, M.; Mochizuki, Y.; Okamoto, T.; Nakazato, K.; Nishiyama, T.; Kikuchi, N. Ciliary Neurotrophic Factor Receptor rs41274853 Polymorphism Is Associated with Weightlifting Performance in Japanese Weightlifters. *J. Strength Cond. Res.* **2020**, *34*, 3037–3041. [[CrossRef](#)]
317. Grishina, E.E.; Zmijewski, P.; Semenova, E.A.; Ciężarczyk, P.; Humińska-Lisowska, K.; Michałowska-Sawczyn, M.; Maculewicz, E.; Crewther, B.; Orysiak, J.; Kostryukova, E.S.; et al. Three DNA Polymorphisms Previously Identified as Markers for Handgrip Strength Are Associated with Strength in Weightlifters and Muscle Fiber Hypertrophy. *J. Strength Cond. Res.* **2019**, *33*, 2602–2607. [[CrossRef](#)]
318. Ahmetov, I.I.; Hakimullina, A.M.; Lyubaeva, E.V.; Vinogradova, O.L.; Rogozkin, V.A. Effect of HIF1A gene polymorphism on human muscle performance. *Bull. Exp. Biol. Med.* **2008**, *146*, 351–353. [[CrossRef](#)]
319. Kostek, M.C.; Devaney, J.M.; Gordish-Dressman, H.; Harris, T.B.; Thompson, P.D.; Clarkson, P.M.; Angelopoulos, T.J.; Gordon, P.M.; Moyna, N.M.; Pescatello, L.S.; et al. A polymorphism near IGF1 is associated with body composition and muscle function in women from the Health, Aging, and Body Composition Study. *Eur. J. Appl. Physiol.* **2010**, *110*, 315–324. [[CrossRef](#)]
320. Ahmetov, I.I.; Gavrilo, D.N.; Astratenkova, I.V.; Druzhevskaya, A.M.; Malinin, A.V.; Romanova, E.E.; Rogozkin, V.A. The association of ACE, ACTN3 and PPARA gene variants with strength phenotypes in middle school-age children. *J. Physiol. Sci.* **2013**, *63*, 79–85. [[CrossRef](#)]
321. Petr, M.; Stastny, P.; Pecha, O.; Šteffl, M.; Šeda, O.; Kohlíková, E. PPARA intron polymorphism associated with power performance in 30-s anaerobic Wingate Test. *PLoS ONE* **2014**, *9*, e107171. [[CrossRef](#)]
322. Mann, D.L.; Dehghansai, N.; Baker, J. Searching for the elusive gift: Advances in talent identification in sport. *Curr. Opin. Psychol.* **2017**, *16*, 128–133. [[CrossRef](#)]
323. Johnston, K.; Wattie, N.; Schorer, J.; Baker, J. Talent Identification in Sport: A Systematic Review. *Sport. Med.* **2018**, *48*, 97–109. [[CrossRef](#)]
324. Baker, J.; Wilson, S.; Johnston, K.; Dehghansai, N.; Koenigsberg, A.; de Vegt, S.; Wattie, N. Talent Research in Sport 1990-2018: A Scoping Review. *Front. Psychol.* **2020**, *11*, 607710. [[CrossRef](#)]

325. Wang, G.; Padmanabhan, S.; Wolfarth, B.; Fuku, N.; Lucia, A.; Ahmetov, I.I.; Cieszczyk, P.; Collins, M.; Eynon, N.; Klissouras, V.; et al. Genomics of elite sporting performance: What little we know and necessary advances. *Adv. Genet.* **2013**, *84*, 123–149. [[CrossRef](#)]
326. Webbhorn, N.; Williams, A.; McNamee, M.; Bouchard, C.; Pitsiladis, Y.; Ahmetov, I.; Ashley, E.; Byrne, N.; Camporesi, S.; Collins, M.; et al. Direct-to-consumer genetic testing for predicting sports performance and talent identification: Consensus statement. *Br. J. Sport. Med.* **2015**, *49*, 1486–1491. [[CrossRef](#)]
327. Pitsiladis, Y.P.; Tanaka, M.; Eynon, N.; Bouchard, C.; North, K.N.; Williams, A.G.; Collins, M.; Moran, C.N.; Britton, S.L.; Fuku, N.; et al. Athlome Project Consortium: A concerted effort to discover genomic and other “omic” markers of athletic performance. *Physiol. Genom.* **2016**, *48*, 183–190. [[CrossRef](#)]
328. de la Chapelle, A.; Sistonen, P.; Lehväsliho, H.; Ikkala, E.; Juvonen, E. Familial erythrocytosis genetically linked to erythropoietin receptor gene. *Lancet* **1993**, *341*, 82–84. [[CrossRef](#)]
329. Schuelke, M.; Wagner, K.R.; Stolz, L.E.; Hübner, C.; Riebel, T.; Kömen, W.; Braun, T.; Tobin, J.F.; Lee, S.J. Myostatin mutation associated with gross muscle hypertrophy in a child. *N. Engl. J. Med.* **2004**, *350*, 2682–2688. [[CrossRef](#)] [[PubMed](#)]
330. Turner, D.C.; Gorski, P.P.; Maasar, M.F.; Seaborne, R.A.; Baumert, P.; Brown, A.D.; Kitchen, M.O.; Erskine, R.M.; Dos-Remedios, I.; Voisin, S.; et al. DNA methylation across the genome in aged human skeletal muscle tissue and muscle-derived cells: The role of *HOX* genes and physical activity. *Sci. Rep.* **2020**, *10*, 15360. [[CrossRef](#)] [[PubMed](#)]
331. Seaborne, R.A.; Strauss, J.; Cocks, M.; Shepherd, S.; O’Brien, T.D.; van Someren, K.A.; Bell, P.G.; Murgatroyd, C.; Morton, J.P.; Stewart, C.E.; et al. Human Skeletal Muscle Possesses an Epigenetic Memory of Hypertrophy. *Sci. Rep.* **2018**, *8*, 1898. [[CrossRef](#)] [[PubMed](#)]
332. Turner, D.C.; Seaborne, R.A.; Sharples, A.P. Comparative Transcriptome and Methylome Analysis in Human Skeletal Muscle Anabolism, Hypertrophy and Epigenetic Memory. *Sci. Rep.* **2019**, *9*, 4251. [[CrossRef](#)]
333. Demirci, B.; Bulgay, C.; Ceylan, H.İ.; Öztürk, M.E.; Öztürk, D.; Kazan, H.H.; Ergun, M.A.; Cerit, M.; Semenova, E.A.; Larin, A.K.; et al. Association of ACTN3 R577X Polymorphism with Elite Basketball Player Status and Training Responses. *Genes* **2023**, *14*, 1190. [[CrossRef](#)]
334. Murtagh, C.F.; Hall, E.C.; Brownlee, T.E.; Drust, B.; Williams, A.G.; Erskine, R.M. The genetic association with athlete status, physical performance and injury risk in soccer. *Int. J. Sport. Med.* **2023**, *in press*. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.